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ABSTRACT 
 
Alzheimer's disease (AD) is a multifactorial, progressive neurodegenerative disease the incidence of which 
increases strongly with age. AD is responsible for the most common form of dementia. Neuropathologically 
it is characterized by the accumulation of beta-amyloid and the formation of intracellular neurofibrillary 
tangles. AD is subdivided into early, EOAD and the more common late onset AD (disease onset ≥65 years), 
LOAD forms. The aetiology of LOAD is still largely unknown. It is widely accepted that genetic and non-
genetic factors (e.g. lipid and glucose metabolism, inflammation) play crucial roles in predisposing the 
disease susceptibility.  
Despite the extensive research to date, only four genes have been proven to either play a direct role in AD 
pathogenesis (genes for amyloid precursor protein, APP; presenilin-1, PSEN-1; presenilin-2, PSEN-2 leading 
to rare autosomal dominant EOAD ) or to significantly increase the disease susceptibility (i.e. apolipoprotein 
E gene, APOE ε4 allele in both EOAD and LOAD). Thus, the only established risk gene for LOAD is APOE. 
Several lines of evidence suggest the existence of additional susceptibility candidate genes for LOAD risk, 
but these still await identification. If we are to develop new strategies to prevent and treat AD, we need to 
understand the background (i.e. predisposing factors like risk genes) of the disease. 
The present study focused on searching for novel risk genes for LOAD but also we explored the contribution 
of apolipoprotein E phenotype (ApoE) to the progression of LOAD in a Finnish population based sample. 
Furthermore, survival of the study population was examined in relation to AD, ApoE phenotype and gender. 
We found that the ApoE ε4 phenotype did not influence the survival once AD had become manifested. 
However, in subjects with AD, ApoE ε4 non-carrier men had an increased risk of mortality compared to 
ApoE ε4 non-carrier women. Also in the whole study population, the risk of death was significantly 
increased in men.  
On the basis of the previous pathophysiological studies we selected and studied genes encoding IL-6, 
cholesterol 24-hydroxylase (Cyp46), α-1-antichymotrypsin (ACT), and peroxisome proliferator-activated 
receptor γ (PPARγ), i.e. genes coding for enzymes involved in lipid or glucose metabolism and 
inflammation. Thus, these are potential biological candidate genes for LOAD risk.  
The IL-6 -174 G allele is over-represented in Finnish ApoE ε4 non-carrier LOAD patients. The CYP46 gene 
dbSNP: 754203 T/C associated significantly with AD. Although dbSNP: 2146238 polymorphism failed to 
show a single allele association between cases and controls, we observed that the CG containing haplotype 
exhibites a modest odds ratio for the risk of AD. The analysis made between a nearby gene SERPINA3, 
which encodes ACT, and AD did not show any significant results. The genetic risk of AD was not 
significantly associated with the studied polymorphisms but the PPARγ Ala12- 478T genotype carriers were 
significantly younger at the onset of dementia than the other AD patients (p= 0.026). 
These findings implicate IL-6 and CYP46 as possible risk genes for LOAD or, possibly they reflect the 
influence of a nearby gene in the AD risk. PPARγ does not seem to play major role in AD risk in Finnish 
LOAD patients.   
To sum up, this data supports the theory that several susceptibility genes interact in the risk of AD or may 
modify the age of the disease onset. And, while ApoE is a significant genetic risk factor for the disease also 
in the aged population, its role in the disease progression is not as evident. 
 
 
National Library of medicine classification: WT 155, QZ 50 
 
Medical Subject Headings: Alzheimer disease/genetics; genes; apolipoproteins E; interleukin-6; cholesterol 24-
hydroxylase; alpha 1-antichymotrypsin; PPAR gamma; aged; men; women; Finland 
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1 INTRODUCTION 
Alzheimer's disease (AD) is a multifactorial, progressive neurodegenerative condition responsible 
for the most common form of dementia. Independent living becomes progressively more difficult 
for AD patients because their cognitive impairment interferes with basic activities of daily living. 
AD frequency increases strongly with age, from less than 1% in people aged 65 to 69 years to over 
20% in those who are 90 years or older. AD is the most important cause of dementia (Lobo et al., 
2000). As the population ages, AD is causing increasing public health and financial concerns 
because of its progressive and devastating effects on affected individuals as well as the substantial 
caregiver burden and the pressure on health care budgets (Winblad et al., 1996). If nothing is done 
to delay the disease onset, it has been suggested that the number of AD patients will quadruple 
within the next 50 years (Brookmeyer et al., 1998). Unless effective prevention or treatment is 
found for the common cause of dementia, the magnitude of the problem will continue to increase. 
However before one can develop of the effective strategies for AD therapy, it is necessary to 
understand the mechanisms of the pathogenesis, disease risk, onset and progression, including the 
genetic predisposition. 
The predisposing factors of AD, with the exception of ageing (Fratiglioni et al., 2000), are still 
largely unknown, although much scientific effort has been expended over the years. While our 
understanding of pathophysiology of the AD remains fragmentary, it is widely accepted that 
genetic, environmental and life style factors play a crucial role in predisposing an individual to the 
disease (Bertram and Tanzi, 2004a). The involvement of vascular risk factors such as high midlife 
blood pressure, cholesterol, glucose intolerance and insulin resistance (Launer et al., 1999; Breteler, 
2000; Kivipelto et al., 2001b) as well as the inflammatory response (McGeer and McGeer, 1998) in 
the aetiology of AD have received considerable attention. The contribution of the genetic factors in 
late-onset AD (LOAD) risk has been suggested to be very high, perhaps as much as 70 % (Bergem 
et al., 1997; Gatz et al., 1997). The difficulties to identify complex disease risk genes and the many 
failures to replicate studies are reflected in the fact that of the almost 100 candidate genes have been 
analyzed to date (Bertram and Tanzi, 2004a) and only four have been proven to either play a direct 
role in AD pathogenesis (genes for amyloid precursor protein, APP; presenilin-1, PSEN-1; 
presenilin-2, PSEN-2) (Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 1995; 
Rogaeva et al., 1998) or to significantly increase disease susceptibility in almost every study 
population analyzed worldwide (i.e. apolipoprotein E gene, APOE, in chromosome 19) (Pericak-
Vance et al., 1991; Poirier et al., 1993; Strittmatter et al., 1993; Dai et al., 1994; Kuusisto et al., 
  
13
1994). The mutations in APP, PSEN-1 and PSEN-2 lead to a rare autosomal dominant form of the 
AD, which usually appears before age of 65 years. However, the majority of AD patients are 
sporadic with onset age usually over 65 years (LOAD). 
The presence of APOE ε4 allele increases the risk of early- and late-onset AD, sporadic and also 
familial forms of AD (Corder et al., 1993; Saunders et al., 1993; Chartier-Harlin et al., 1994; van 
Duijn et al., 1994). The APOE ε4 carriers have an earlier onset of the disease compared to non-
carriers (Corder et al., 1993; Poirier et al., 1993; Tsai et al., 1994) but the results from those studies 
which have examined the influence of ε4 allele in the progression of AD are controversial (Corder 
et al., 1995; Frisoni et al., 1995; Stern et al., 1997; Craft et al., 1998). Part of the LOAD cases can 
be explained by the presence of the APOE ε4 allele (Slooter et al., 1998; Daw et al., 1999). While 
the magnitude of the effect of the APOE ε4 allele as a risk factor for LOAD is age (Slooter et al., 
1998) and ethnicity dependent (Corbo and Scacchi, 1999), the importance of the other genetic and 
environmental risk factors may increase in aged populations while that of the ε4 allele decreases 
(Slooter et al., 1998). Further, although almost none of the 100 genes that have been tested for 
association with AD have yielded consistent results, several lines of evidence do point to the 
existence of additional susceptibility risk genes for LOAD risk, not yet identified (Daw et al., 1999; 
Bertram and Tanzi, 2004a).  
Regions on at least nine other chromosomes in addition to chromosome 19 (probably representing 
APOE) have emerged in full genome screens, showing evidence for genetic linkage or association 
with P-values = 0.01 (Myers et al., 2002; Blacker et al., 2003) with the strongest evidence for 
linkage on chromosome 10 (Myers et al., 2002). Similar findings have been obtained for several 
additional genes, which are involved in AD-related pathophysiological cascades, such as the low 
density lipoprotein receptor-related protein (LRP) (Wavrant-DeVrieze et al., 1999), cystatin-C 
(CST3) (Finckh et al., 2000), cathepsin-D (CTSD) (Papassotiropoulos et al., 2000), bleomycin 
hydrolase (BLMH) (Montoya et al., 1998), interleukin-1 (IL1) (Grimaldi et al., 2000), interleukin-6 
(IL-6, according to HUGO Nomenclature IL6) (Bagli et al., 2000; Arosio et al., 2004; Capurso et 
al., 2004) and neprilysin (NEP) (Helisalmi et al., 2004). Some genes, like the gene for insulin-
degrading enzyme (IDE, located on chromosome 10q23.3 close to a region of linkage for LOAD) 
represent both positional and biologic candidates for LOAD susceptibility (Bian et al., 2004). 
Polymorphisms of these and of numerous other genes have been suggested as potential 
susceptibility factors for LOAD, and also possibly modifying the onset of the disease. 
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Novel AD genes will not only provide valuable clues for the development of novel therapeutic 
approaches, but will also allow the development of new genetic risk profiling strategies that will 
become an essential prerequisite for early prediction and prevention of this devastating disorder. 
The Finnish population is ideal for the study of genetic factors of diseases since a small number of 
founders brought a random assortment of disease genes to Finland.  As a result of national and 
regional isolation, little further mixing of genes has occured. Therefore, the population has 
remained, so far, genetically homogenous, but also enriched with rare genetic mutations (Norio, 
2003a; Norio, 2003b). 
The present study is part of a larger project focusing on searching for novel risk genes for LOAD in 
the Finnish population. The studied candidate genes encode cholesterol 24-hydroxylase (Cyp46, 
referred to in the literature also as Cyp46a1), IL-6 and peroxisome proliferator-activated receptor γ 
(PPARγ) each of these enzymes acting in lipid metabolism (Papassotiropoulos et al., 2001; Raffai 
and Weisgraber, 2003; Cock et al., 2004), or in glucose metabolism and inflammation (Combs et 
al., 2000; Papassotiropoulos et al., 2001; Cock et al., 2004) thus they represent biological candidate 
genes for AD risk. The gene encoding α-1-antichymotrypsin (ACT), previously reported to 
associate with AD (Kamboh et al., 1998), was examined due to its proximity of cholesterol 24-
hydroxylase gene (CYP46, according to HUGO nomenclature CYP46A1). Furthermore, our purpose 
was to study the contribution of apolipoprotein phenotype (ApoE), which also modulates 
lipoprotein transport and metabolism (Mahley, 1988; Mahley and Rall, 2000), in the progression of 
AD and in survival of the study population. 
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2. REVIEW OF THE LITERATURE 
2.1. Alzheimer's disease (AD) 
2.1.1. Epidemiology of dementia and AD  
Dementing illnesses increase in the populations with advancing age. In a European collaborative 
study published in 2000, the prevalence of dementia in the elderly was 6.4 %, but it ranged from 
0.8% in the group age 65 to 69 years and almost one third at age 90 years or older (Lobo et al., 
2000). Currently in Finland, approximately 110 000 individuals suffer from mild to moderate 
dementia. As the population ages, the proportion of the demented subjects will continue to increase.  
AD is the most common form of age-related dementia with onset during middle age but more 
commonly in the later years of life. The lifetime risk of AD varies with age, sex, and life 
expectancy (Seshadri et al., 1997). The incidence rate of AD increases from approximately 1% 
annually among people aged 65 to 70 years to approximately 6% to 8 % for people over age 85 
(Mayeux, 2003a). The lifetime risk of AD varies from 12% to 19% for women over the age of 65 
years and from 6% to 10% for men (Seshadri et al., 1997).  
The duration of AD varies considerably with values ranging from 2 to 16 years after disease onset. 
The mean survival time for patients with AD was 3 to 7 years in two recently published studies 
(Wolfson et al., 2001; Fitzpatrick et al., 2005). For people over the age of 65, AD represents the 
eighth leading cause of death (Hoyert and Rosenberg, 1997). 
In European populations, the overall prevalence of AD was 4.4 % (Lobo et al., 2000). The 
prevalence is higher among Afro-Americans and Hispanics compared with Caucasians living in the 
United States (Perkins et al., 1997; Gurland et al., 1999), but not among Africans in their native 
countries (Ogunniyi et al., 2000). Both the incidence and duration rates of illness influence the 
prevalence rate. Thus the prevalence of subjects surviving with clinically diagnosed AD varies with 
age. Before age 65 the disease is rare (<0.5% of this age group), but it increases by age 85 and 
older. Among the population over 85 years, between 13% to over 30% have this disease, depending 
on which the stage of disease severity is examined i.e. from mild to severe forms (Rocca et al., 
1991; Skoog et al., 1993; Ott et al., 1995; Hy and Keller, 2000; Lobo et al., 2000; Polvikoski et al., 
2001). Over half of all demented patients were diagnosed as having AD (Hy and Keller, 2000; Lobo 
et al., 2000).  
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2.1.2. Neuropathology and pathogenesis of AD  
The characteristic histopathologic changes of AD at autopsy include neuronal loss, neurofibrillary 
tangles (NFTs) and neuritic plaques. Progressive neuronal dysfunction and loss of neurons in 
specific regions of the brain are associated with the clinical expression of the disease (Di Patre et 
al., 1999). Total neuron losses vary from 40% to 50% in the hippocampus (Mann et al., 1985), up to 
79% in the nucleus basalis (Whitehouse et al., 1982) and from 15% to 58% in the cortex this being 
more severe in the temporal than in the parietal area (Hansen et al., 1988). Nerve cell loss in 
specific nuclei is accompanied by neurochemical deficiencies, and the combination of neuronal loss 
and neurotransmitter deficits leads to the appearance of the dementia syndrome. The destructive 
aspects involve the neurochemical deficits that disturb cell-to-cell communications, abnormal 
synthesis and accumulation of cytoskeletal proteins (e.g., tau) and beta-amyloid (Aβ), loss of 
synapses, decreased amount of dendrites, damage through oxidative metabolism and cell death (Di 
Patre et al., 1999).  
The microtubule-associated protein, tau, appears to be critical for normal neuronal activity. The best 
established cause of dysfunctional tau in AD is the abnormal hyperphosphorylation of tau. This not 
only results in the loss of tau effect and stabilizing microtubules but also the modified form may 
have a toxic function and promote disruption of microtubules. The affected neurons react to the 
toxic tau by synthesizing new normal tau and by packaging the abnormally hyperphosphorylated 
tau into neurofibrillary tangles, twisted ribbons and straight filaments. Gradually and progressively 
the affected neurons degenerate (Iqbal et al., 2005). 
The accumulation of non-soluble Aβ (Aβ42) is to date widely accepted as a central pathogenic 
event and hallmark of pathological diagnosis in AD (Hardy and Selkoe, 2002). All mutations 
known to cause AD (mutations in APP, PSEN1 and PSEN2) increase the production of Aβ peptide 
(Hardy and Selkoe, 2002; Parihar and Hemnani, 2004). This protein is derived from amyloid 
precursor protein (APP) and, according to many studies when aggregated in a beta-pleated sheet 
configuration is neurotoxic (Hardy and Selkoe, 2002; Parihar and Hemnani, 2004). Aβ forms the 
core of neuritic plaques surrounded by dystrophic neurites, astrocytes and microglia. Unstructured 
amyloid consisting of diffuse plaques is also seen in AD brain, but they are detected also in normal 
brain. Diffuse plaques are not surrounded by neurites. In addition to extracellular form, β-amyloid is 
seen intracellulary in neurons (Selkoe, 2000). Amyloid plaques represent a side or final product in 
AD pathogenesis but the toxicity of Aβ and other amyloidogenic proteins is not mediated the 
through insoluble amyloid fibrils but it is the soluble oligomeric species which appear to be more 
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damaging. These soluble species include Aβ-derived diffusible ligands (ADDLs having globular 
structures) and protofibrils (strings of the globular structures) (De Felice et al., 2004). 
Pathological alterations other than NFTs and plaques have also been shown to develop in AD brains 
and to parallel the severity of the clinical picture. At least three additional pathophysiological 
processes have been suggested to play a key role in the pathogenesis of AD: loss of synapses, 
inflammatory mechanisms and cerebral amyloid angiopathy (CAA).  Loss of synapses in AD frontal 
cortex has been well documented by synaptophysin immunoreactivity and ultrastructural analysis 
and this has been shown to correlate with the degree of cognitive deficit (Cummings et al., 1998). 
Plaques are closely associated with a locally induced, non-immune mediated, chronic immune 
process. The role of inflammatory molecules in the pathological process is not fully understood, but 
numerous studies indicate that these molecules may be involved in the proposed Aβ-driven 
pathogenic cascade (van Gool et al., 2003). The concept that Aβ peptide is able to induce a local 
inflammatory response has received strong support by the finding that fibrillar Aβ binds to the 
complement factor C1 and activates the classical complement pathway in an antibody independent 
fashion (Rogers et al., 1992).The activated complement products may have a crucial role in the 
recruitment and activation of microglia (Eikelenboom and Veerhuis, 1996). Activated microglia 
produce numerous pro-inflammatory cytokines such as interleukin-1 and -6 (IL1 and IL-6) and 
tumour necrosis factor α (Griffin et al., 1989; Dickson et al., 1993). These cytokines may in turn 
induce further dysregulation of APP and local production of complement proteins and acute phase 
proteins (van Gool et al., 2003) as well as exacerbating plaque pathology and enhancing the 
hyperphosphorylation of tau and the subsequent development of neurofibrillary tangles (Kitazawa 
et al., 2004). On the other hand, microglial cell density in the white matter has been shown to be 
remarkably higher than that in the neocortex, suggesting that inflammatory responses involving the 
white matter may be more prominent than those in the gray matter and obviously this is not directly 
related to the development of the pathological features considered to be most characteristic of AD 
(Di Patre et al., 1999).  
Amyloid can be deposited in the walls of blood vessels, more often arteries and arterioles, of the 
central nervous system. This phenomenon is known as CAA, which is an additional pathological 
process of AD. The other major clinicopathological manifestations of CAA include also cerebral 
hemorrhage and ischemic lesions. (Revesz et al., 2003). In addition to CAA, profound changes in 
cerebral microvessels and cerebral infarctions, independently of amyloid deposition, have often 
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been found in AD subjects. There are findings to indicate that almost 35% of AD subjects exhibit 
evidence of cerebral infarction at autopsy (Kalaria, 2003).  
In addition, neuropathological overlaps have been reported between many neurodegenerative 
disorders. As many cases of other neurodegenerative diseases exhibit associated AD pathology, AD 
patients may also have pathological changes typical to other neurodegenerative diseases e.g. 
presence of lewy bodies or pathological changes in substantia nigra (Armstrong et al., 2005).  
Pathological markers of AD develop in vulnerable brain regions in an uneven manner and at a 
variable rate. Indeed, cross-sectional studies indicate that the spreading of pathological alterations in 
AD does not appear in different brain regions at the same time but tends to begin in certain areas 
(namely, transentorhinal and  entorhinal cortex and hippocampal formation), subsequently 
spreading to other areas (to the limbic areas of brain and finally to the neocortex) as the disease 
advances (Braak and Braak, 1995).  Progression of cognitive impairment and manifestation of AD 
may not exclusively correlate with increasing plaque and NFT densities or with numerical changes 
of other pathological changes but, may also depend on the affected specific brain regions and the  
related brain changes. Involvement of subcortical nuclei (such as cholinergic forebrain nuclei) are 
crucial to memory functions and this contributes significantly to the cognitive impairment 
(Cummings et al., 1998). 
Therefore, based on the available data, it is evident that AD, especially LOAD, may result from 
several parallel pathological changes that vary from patient to patient in intensity and distribution 
(Cummings et al., 1998). While the initiating factors and other antecedent events leading to the 
neurodegeneration in AD need to be clarified, it is widely accepted that many genes, most of them 
not yet identified, play an essential role in predisposing to disease onset and in modifying the course 
of the disease in conjunction with several non-genetic factors (Papassotiropoulos et al., 2001; 
Bertram and Tanzi, 2004a). 
2.1.3. Aetiologies, predisposing and protecting factors of AD  
The aetiology of AD, especially in the case of LOAD, is heterogenetic and multifactorial. Several 
genetic and non-genetic factors determine the risk for the development of AD and modify onset age 
and the course of the disease (Table 1). The real contribution, importance and interactions of many 
of these factors remain still unclear and are the topics of intense research (Bertram and Tanzi, 
2004a). 
Table 1. The factors involved in modifying AD risk. 
 Hypotheses 
Power of evidence Predisposing factors Protective factors 
Strong • Clinical condition: Advanced age, Down's 
syndrome 
• Familial aggregation: First degree relatives with AD 
• Genetic factors: APP, PSEN1, PSEN2, APOE ε4 
 
• Genetic factors: APOE ε2 
 
Moderate • Clinical condition: High midlife blood pressure 
• Female gender 
• Sosiodemographic factors: Low formal education, 
poor support during early years of life, lack of 
social and intellectual leisure-time activities 
 
• Sociodemographic factors: higher educational level, 
intellectual leisure-time activities 
Limited/insufficient • Other genetic factors 
• Clinical condition: Cardio- and cerebrovascular 
diseases, other related vascular risk factors like high 
midlife cholesterol, high blood pressure or 
cholesterol in advanced age, diabetes, glucose 
intolerance, hyperinsulinemia, obesity. Depression. 
Previous severe or repeated head trauma. Lack of 
folate/B12-vitamin 
• Sociodemographic/ life style factors: low 
socioeconomic status, lack of physical activity, 
smoking, heavy intake of alcohol 
• sociodemographic /life style factors: social activity, 
physical leisure activities, moderate alcohol 
consumption 
• Medication: History of estrogen replacement 
therapy in postmenopausal women, NSAIDs, lipid 
lowering agents, blood pressure therapy, vitamins 
(Kivipelto 2002b; Mayeux, 2003a; Gorelick, 2004) and updated using summary of the Swedish Council on Technology Assesment in Health 
Care (SBU) report, 2006. Available in www.sbu.se/content0/document/Demens_sammanfattning.pdf).
2.1.4. Clinical features 
AD preferentially affects individuals above 65 years. Clinically AD is characterised by an insidious 
onset and a progressive decline of memory and other cognitive functions interfering with daily 
functions at home and impairing occupational as well as social life. The deterioration of the 
cognitive functions is often followed by behavioural and mental disturbances. Motor difficulties 
appear in the late course of the disease. The disease progresses from a mildthrough a moderate to a 
severe phase with mounting severity of symptoms with the patient  and need of, finally requiring 
continuous, assistance and care prior to death. The symptoms and severity of AD correlate with the 
neuropathological progress of the disease. The individual prognosis of AD varies but the expected 
survival time after manifestation of the disease is ten years, varying from two to 16 years (Reisberg 
et al., 1999). 
2.1.5. Diagnosis of AD 
Dementia is defined as "a loss of intellectual abilities of sufficient severity to interfere with social or 
occupational functioning" (APA, 1987). The specific diagnosis of AD is generally clinical and 
based of the symptoms and findings typical to AD. No specific biological markers are in use in 
routine AD diagnosis. The most widely used clinical criteria in the diagnosis of dementia and AD 
are defined in the Diagnostic and Statistical Manual of Mental Disorders, 3rd revised edition (DSM 
III-R) (APA, 1987) or 4th edition (DSM IV) (APA, 1990) and the criteria proposed by the National 
Institute of Neurological Communicative Disorders and Stroke and the Alzheimer disease and 
Related Disorders Association (NINCDS/ADRDA) (McKhann et al., 1984). According to 
NINCDS/ADRDA criteria (McKhann et al., 1984) the diagnosis of AD is classified into three 
categories- possible, probable and definite AD. The criterion for definite AD requires a 
histopathological confirmation of clinically probable AD. The criteria for neuropathological 
diagnosis of AD are defined by the Neuropathology Task Force of the Consortium to Establish a 
Registry for Alzheimer's Disease (CERAD) (Mirra et al., 1991). In clinical practice also the 
International Classification of Diseases, 10th revision criteria (ICD-10) (WHO, 1993) are used.  
The patient has probable AD (McKhann et al., 1984) when the presence of dementia has been 
ascertained by a questionnaire and confirmed by typical findings in neuropsychological tests (like 
disturbances in memory, typically in episodic memory, in executive functions, and in language), 
plus that there is a gradual onset and progression of the symptoms. Other disorders which could 
possibly cause memory disturbances need to be absent. The dementia interferes with the patients 
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activities of daily living, and it induces altered patterns of behaviour. Regularly used laboratory 
analyses (blood and CSF tests) are normal. In the early phase of the disease, brain computed 
tomography is often normal but in magnetic resonance imaging, hippocampus atrophy can be seen. 
In serial observations, progressive brain atrophy appears. Electroencephalography is normal or 
some minor non-specific changes can be found. The patient has possible AD when he/she has also 
another brain disorder or systemic illness that is sufficient to cause dementia but is not considered to 
be the origin of the memory disease or the presentation of dementia varies compared to typical AD.  
2.2. Subtypes of Alzheimer's disease 
Previously the term Alzheimer's disease was used in the case of early onset (onset age <65 years) 
dementia of AD type. The late-onset type (onset age ≥ 65 years) of AD was called senile dementia. 
The typical brain pathology (e.g. NFT, plaques) of the disease are similar in EAOD and LOAD 
(Raskind et al., 1995) but in recent reports, certain differences have also been noted (e.g. the extent 
of atrophy in different parts of brain) (Frisoni et al., 2005). Furthermore, according to several 
studies, EOAD and LOAD patients have exhibited a different phenotype in several studies (Raskind 
et al., 1995; Devi et al., 2004; Hori et al., 2005) and, inheritance of AD shows an age-related 
dichotomy (Tanzi, 1999). Rare but highly penetrant mutations of PSEN1 on chromosome 14, 
PSEN2 on chromosome 1, and the amyloid protein precursor (APP) on chromosome 21 transmitted 
in an autosomal dominant manner have so far been found to account EOFAD. Instead, common 
polymorphisms like the APOE on chromosome 19 and alpha2-macroglobulin (A2M) on 
chromosome 1, with low penetrance appear to have their greatest effect as risk factors and/or 
genetic modifiers on the more frequent disease form LOAD (Tanzi, 1999).  
Familial and sporadic AD was previously distinguished only by family history of other affected 
relatives. During the past decade genetic studies have increased our knowledge on AD aetiology 
and today molecular genetics provides an alternative approach to identify familial AD patients with 
defined genetic abnormalities. Nowadays, according to the genetic point of view, AD may be 
categorized into three forms: autosomal dominant familial AD, familial AD without clear 
Mendelian inheritance (familial aggregation) and the sporadic AD without familial aggregation 
(Papassotiropoulos et al., 2001). Only a minority (<5%) of all AD cases can be explained by the 
presence of known genetic factors (APP, PSEN1 and PSEN2) responsible for the autosomal 
dominant, early onset familial form AD (Rocchi et al., 2003). However, 10 % of all AD cases are 
estimated to be autosomal dominant familial cases. The familial aggregation of AD may be due to 
both genetic and environmental risk factors in families without any clear mode of inheritance, 
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representing 30 % of all AD cases (Farrer et al., 1989). Sixty percent of all AD cases have been 
estimated to be without familial aggregation and they are called "sporadic AD" (Papassotiropoulos 
et al., 2001). Some clustering in families with longevity may be due to chance alone. Sporadic AD 
often manifests close to the terminal part of the life span (Tanzi, 1999). However, some contribution 
of genetics factors (e.g. modifying the age of onset or disease risk like APOE) in LOAD has been 
suggested to be higher, even 75 % of the disease risk (Gatz et al., 1997).  
2.3. A strategy to identify and study candidate risk genes in complex diseases  
Complex and heterogenetic diseases like coronary heart disease, arterial hypertension, diabetes and 
LOAD have no simple mode of inheritance. Furthermore, mutations and polymorphisms in multiple 
genes involved with these diseases interact with each other and also with non-genetic factors 
associated with disease risk. The genetic analyses of common and complex diseases have proved to 
be challenging. To date, almost 100 candidate risk genes have been analyzed for AD and only four 
(APP, PSEN, PSEN2 and APOE) have been proved to associate with AD in several studies. Only 
one of these genes (APOE) has also associated with LOAD (Bertram and Tanzi, 2004a). In 
conventional family-based linkage analyses, these difficulties are related, in addition to the complex 
inheritance and heterogeneity, to the limited number of affected members in different generations 
available for genetic and phenotype analyses, the presence of phenocopies and to the possibility that 
carriers of the disease causing mutations or polymorphisms die before the appearance of the 
symptoms of late-onset disease. Therefore, alternative methods like linkage disequilibrium and 
association-based population and case-control studies have been used for identifying novel genes 
for LOAD and other complex diseases. However also in these studies, several factors such as 
sampling differences and stratification of the study population, make it difficult to identify and 
consistently replicate analyses of susceptibility in LOAD-related genes or other complex disease 
genes. Nevertheless, the LOAD risk caused by these susceptibility genes and consequently the 
importance in public health may be considerable due to their relatively common frequency in the 
population (Bertram and Tanzi, 2004a).  
2.3.1 Candidate risk gene 
Candidate genes are chosen as "positional candidates" or as "biological candidates" for the disease. 
"Positional candidate genes" are chosen from chromosomal regions implicated by genetic linkage or 
association. These candidate genes may also be "biological candidates" in the case when they have 
a positive association with the disease pathobiology. When the chosen candidate genes are purely 
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"biological candidates" implicated by pathobiological studies of disease under study then the chosen 
genes exhibit no evidence of genetic linkage or association. 
2.3.2. Linkage studies 
A common strategy to localize highly penetrant genes is linkage analysis. The co-segregation of 
specific genetic markers and disease phenotype is examined in extended families with several 
affected members. Linkage is derived from the consept of the distances between the two specific 
genetic loci. When different loci are situated in different chromosomes or are distant from each 
other in the same chromosome (and recombinations are possible), they are transmitted in meiosis 
independently of the other loci to the offspring. The specific loci are in linkage when they are 
located in the same choromosome, close enough that recombinations are rare between them. These 
close genetic alleles are transmitted to the next generation in a combination called the haplotype. 
The recombination fraction is a measure of genetic distance (1% recombination= 1 centiMorgan 
(cM)≈ 1 million nucleotides as a physical distance). The analysis of genetic linkage between two 
loci determines whether and how much the recombination fraction is smaller than 50%. For linked 
loci, it is less than 50% (likelihood that two loci are truly inherited in linkage, not inherited by 
coincidence). The origin of this strategy is that every subject carries two alleles at each gene locus 
transmitting with a probability of 50% one of two alleles from each locus to their offspring. In the 
estimation of likelihood of the true linkage, the most frequently used method is the logarithm of 
odds (lod –score method). Linkage is considered significant when the lod score reaches a value of 3 
or more.  
The strategy of linkage analysis and subsequent positional cloning has been very successful in 
monogenic disorders and in some rare variants of complex diseases like in EOFAD. This analytic 
approach has led to the identification of all three known EOAD genes on chromosomes 21 (APP), 
14 (PSEN1) and 1 (PSEN2). However, the practical problems described above in complex and 
heterogenic diseases reduces the feasibility of using linkage studies in LOAD. It has been suggested 
that in complex and heterogenetic diseases, the loci associated with the disease under study may be 
identified more readily by studies of association and linkage disequilibrium (Risch and Merikangas, 
1996). 
 
 
  
24
2.3.3. Linkage disequilibrium 
In linkage disequilibrium or allelic association, certain alleles located in close genetic loci are 
inherited together more often than expected according to the mathematical models. No 
recombinations, not even through several generations, are observed if these certain alleles are 
located close enough (Strachan and Read, 2004). 
2.3.4. Association studies 
Based on the pathophysiological studies related to the theory of the disease aetiology (e.g. in AD 
genes involved with Aβ, as well as other AD related pathways like inflammation, lipid metabolism 
etc.) or/and experimental findings (e.g. linkage studies), genes involved in disease pathogenesis are 
chosen as candidate genes in association studies. Markers or possible risk alleles e.g. single 
nucleotide polymorphisms, SNPs of these genes, which ideally alter gene function, are expected to 
be associated with the risk for the development of the disease. This hypothesis can be tested by 
cocducting an assessment of the frequency of the allelic or genotype variations in a sample of AD 
patients and control subjects in population or family-based or in classical clinical case-control 
studies. Evidence that the APOE ε4 allele was as a risk factor for AD was derived from numerous 
association studies while linkage analyses failed to replicate that finding. Furthermore, the 
replicability of the association studies in independent study populations and the possibility to study 
the haplotype structure of the gene increases the power of this method.  
Homogeneity in the study population is crucial in the selection of the cases and controls for 
association studies. Heterogeneity, as well as stratification of the study population may skew the 
results. Concern about population stratification, control selection and prevalent case lead to biases 
and, therefore false positive results as well as controversial results, but these can be minimized by 
careful study design and by appropriate statistical analysis (Edland, 2004; Bertram and Tanzi, 
2004a) 
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2.4. Genetics of Alzheimer's disease 
Table 2. The established Alzheimer's genes and their functions. 
Gene Protein Chromosomal 
Location 
 
Associations Model of 
Inheritance 
Mutations/ 
Nb 
Affected 
families/Nb 
Onset age/ 
years 
(range) 
Pathogenic 
relevance 
APP Amyloid 
precursor protein 
21q21.2 EOFAD:+ 
LOAD: - 
Autosomal-
dominant 
25 71 52 (35-60) ↑Aβ 
aggregation 
(↑Aβ42/40-
ratio) 
 
PSEN1 presenilin 1 14q24.3 EOFAD:++ 
LOAD:+/- 
Autosomal- 
dominant 
155 315 44 (24-60) ↑Aβ 
aggregation 
(↑Aβ42/40-
ratio) 
 
PSEN2 presenilin 2 1q31-42 EOFAD:+ 
LOAD:- 
Autosomal -
dominant 
10 18 57 (56-71) ↑Aβ 
aggregation 
 (↑Aβ42/40-
ratio) 
 
APOE apolipoprotein E,  
ε4 allele 
19q13.32 EAOD:modifiera 
LOAD:modifier 
complex  n.a. n.a. modifies 
onset age 
↑Aβ 
aggregation 
↓Aβ clearance 
 
N= number; EOFAD = early -onset familial Alzheimer's disease; EOAD = early -onset Alzheimer's disease; LOAD = late -onset Alzheimer's 
disease; + = positive associations in several studies;  -.= mostly negative association findings; +/-: both positive and negative association 
findings; n.a.= not applicable; modifier = modifies disease risk, age at onset and cognitive performance after disease onset (Marra et al., 2004); 
Aβ = beta- amyloid; ↑ = increase; ↓= decrease 
The table is modified according to publications by Tanzi and Bertram (Tanzi and Bertram, 2005), Bertram and Tanzi (Bertram and Tanzi, 2004a) 
and, a (Marra et al., 2004) and updated on 6th Mar 2006 using b The Alzheimer's Disease Mutation Database (URL: 
http://www.molgen.ua.ac.be/ADmutations/). 
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2.4.1. Causative genes of early -onset AD 
Less than half of the EOFAD cases are explained by the initial well known mutations found in APP, 
PSEN1 and PSEN 2 genes (Table 2). All but one of the PSEN1 mutations are 100% penetrant and 
are sufficient (but not necessary) to cause AD (Tanzi, 1999). (Table 2).  
2.4.1.1. APP 
Originally chromosome 21 had been selected for AD research from studies into the Down's 
syndrome. These subjects exhibit neuropathological changes typical of AD (Mann et al., 1985; 
Wisniewski et al., 1985). The first linkage between the gene encoding APP (Table 2) and familial 
AD was noted in 1987 (Goldgaber et al., 1987; Robakis et al., 1987; Tanzi et al., 1987). In EOAD 
families a common point mutation of APP gene in codon 717 leading to change of valine to 
isoleucine ("London mutation") was first described in 1991 (Goate et al., 1991). Currently, a total of  
18 mutations, e.g. “Swedish” (double mutation at codons 670 and 671) and “Arctic” (at codon 693) 
mutations (Mullan et al., 1992; Nilsberth et al., 2001) have been identified in several families 
(Table 2). In all, 14 % of all EOAD families carry these known APP gene mutations 
(http://www.molgen.ua.ac.be/ADmutations). Almost all mutations are located on exon 17 (89%) 
and the remainder on exon 16 and consequently they are close to or within the Aβ peptide coding 
domain. Also genetic variations in the regulatory APP gene promoter region have been evaluated 
without any clear-cut findings (Wavrant-DeVrieze et al., 1999; Athan et al., 2002).  
The APP 717 mutations produce more than doubling of the amounts of the insoluble forms of Aβ 
peptide (Aβ42-43), which rapidly aggregates to form amyloid depositions, initiating the formation 
of neuritic and senile plaques (Jarrett et al., 1993; Suzuki et al., 1994) though it is believed that, 
some mutations might be able to alter metabolism of APP (De Jonghe et al., 2001; Nilsberth et al., 
2001).  
The APP gene includes 18 exons and encodes for at least eight different isoforms of APP. The exon 
15 is presented always in APP isoforms expressed in neurons. APP is a transmembrane protein with 
a long extracellular N-terminal domain and a short intracellular C-terminal domain (Hardy, 1997) 
(Figure 1). It undergoes at least two proteolytic cleavages (the possible cleavage pathways involve 
α-secretase, β- secretase or γ- secretase or combinations of these enzymes) in all cells. The 
membrane associated α-secretase cleaves APP within the Aβ- domain, leading to soluble and non-
amyloidogenic formation of Aβ-peptide (Aβ40). The cofunction of β- secretase and γ- secretase is 
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critical since this leads to the release of Aβ-peptides with 42 or 43 amino acids (Aβ42- Aβ43), 
which are more fibrillogenic and possibly neurotoxic (Koo and Squazzo, 1994). The biological 
function of APP still remains poorly understood. In vitro studies suggest that secreted APP may 
stimulate cell proliferation and adhesion as well as support nerve growth factor-induced neurite 
outgrowth of certain cells (Milward et al 1992, Saitoh et al 1989). 
 
 
 
 
 
 
 
 
Figure 1. Domain structures of APP and secretase ( α, β, γ and ε) cleavage sites  in APP. 
Depending on the cleavage site of γ-secretase, either 40 or 42 Aβ-peptide is produced. Non-
amyloidogenic peptides (P3 and  βAPP Intracellular domain, AICD) are also produced.  
 
2.4.1.2 Presenilins 
A linkage between AD and a locus on the long arm of the chromosome 14 (Van Broeckhoven et al., 
1992) was detected in 1992 and three years later Sherrington et al identified and isolated PSEN1 
(Table 2) by a positional cloning strategy (Sherrington et al., 1995). The PSEN2 gene was found 
based on its homology to the PSEN1 and it was localised to the long arm of chromosome 1 (Table 
2). Both genes consist of 13 exons. To date there are 152 mutations found on these genes in almost 
300 different EOAD families, most of them carrying the PSEN1 mutations (Table 2) 
(http://www.molgen.ua.ac.be/ADmutations). Over 70 % of all known PSEN1 mutations are located 
on exons 5-8, with the others on exons 4, 10-12 and five mutations on introns 4, 8 or 9. The most 
pathogenic mutations of PSEN1 are mostly missense substitutions, two are nucleotide insertions 
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(one of them is not causative for AD but does cause frontotemporal dementia), three trinucleotide 
deletions, one hexanucleotide deletion and two splicing defects. The ten pathogenic missense 
mutations found in the PSEN2 exist on exons 4, 5 7 and 12 
(http://www.molgen.ua.ac.be/ADmutations). While several PSEN mutations have been associated 
EOFAD, an intronic PSEN1 mutation has been claimed to be in association of sporadic LOAD, but 
this hypothesis is not supported by other studies (Kehoe et al., 1996; Nishiwaki et al., 1997; Scott et 
al., 1997).  
The mutant PSEN1 causes increased production of Aβ peptide in cell lines (Citron et al., 1997). 
PSEN1 encodes a membrane protein, presenilin 1 (PSEN1), which influences γ-secretase activity 
which in turn is necessary for cleavage of Aβ from APP (Haass and De Strooper, 1999). The mutant 
PSEN1 has proven to increase also intracellular levels of the fibrillogenic Aβ42 (in endoplasmic 
reticulum and in Golgi compartments) (Sudoh et al., 1998).  
The molecular mechanisms underlying the pathogenic effect of presenilins are not fully understood. 
Recent findings suggest that four membrane proteins (presenilin, nicastrin, aph-1 and pen-2) contain 
the limiting components of γ-secretase and when expressed together they form the active enzyme 
complex which catalyses the intramembrane proteolysis of Notch and APP protein and other 
substrates (Kimberly et al., 2003). 
2.4.2 Apolipoprotein E 
ApoE is a polymorphic protein synthesized in several organs but mainly by liver and brain in 
neurons and astrocytes. It is synthesized also by macrophages and monocytes. ApoE is crucial in 
lipid transport since it is a constituent of several classes of plasma lipoproteins as well as being the 
ligand that mediates the uptake of lipoprotein particles into cells via the low density lípoprotein 
receptor (LDLR) and LRP (Mahley, 1988). Furthermore, it is involved in the mobilization and 
redistribution of cholesterol during neuronal growth and after injury (Mahley and Rall, 2000) but is 
crucial in many other functions such as nerve regeneration, immunoregulation and activation of 
several lipolytic enzymes (Mahley and Rall, 2000).  
ApoE contains 299 amino-acid residues, the amino terminal domain (residues 1-191) is a stable 
globular structure containing the receptor binding site. The carboxy-terminal domain (residues 216-
299) is helical, less stable and this region contains the lipoprotein binding sites (Weisgraber, 1994). 
Utermann and colleagues have first described a polymorphism of ApoE in human serum (Utermann 
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et al., 1979). ApoE has three major isoforms, ApoE ε2, ApoE ε3  and ApoE ε4. A single locus with 
three alleles of APOE gene is responsible for this pattern. The three ApoE isoforms differ from each 
other at two sites, at residues 112 and 158 (Figure 2). 
 
 
 
 
Figure 2. Apolipoprotein polymorphisms (modified according to Rocchi et al., 2003) 
 
The prevalence of the APOE allele differs depending of the ethnic background and also 
geographical location. While the APOE ε2 allele is the rarest isoform with variations between 0.00 
in Mayans and 0.13 and 0.14 respectively in New Guinea and China, the APOE ε3 allele is the 
commonest (range 0.49 in Sudan and 0.91 in Mayans) in all populations. The prevalence 
frequencies of APOE ε4 allele differ among populations (range 0.05-0.37, respectively, for 
Taiwanese and Papua New Guineans) (Gerdes et al., 1992; Siest et al., 1995). In Finland, APOE ε2 
allele prevalence is lowest in children, becoming more common in the very elderly i.e. individuals 
with this allele live longer than their counterparts with the other alleles (Table 3) (Louhija et al., 
1994). Furthermore, the ε4 allele frequency is higher in women than in men (Payami et al., 1996). 
In Finland, ApoE isoform frequencies appear to be rather similar in different parts of the country 
(Ehnholm et al., 1986; Lehtimaki et al., 1990; Lehtovirta et al., 1995; Kivipelto et al., 2002a). 
Table 3. The prevalence of ApoE alleles in Finland (Louhija et al., 1994). 
APOE 3-18 years 
N = 1577 
20-55 years 
N = 615 
Centenarians 
N=179 
ε2 0.04 0.04 0.07 
ε3 0.77 0.73 0.84 
ε4 0.19 0.23 0.08 
E2: NH2 Cys Cys COOH
E3: NH2 Cys Arg COOH
E4:  NH2 Arg Arg COOH
112 158
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It has been proposed that the ApoE isoforms may posses distinct binding properties to Aβ peptide 
(Strittmatter et al., 1993) and tau-protein (Strittmatter et al., 1994) and that this might be the 
mechanism by which ApoE mediates its action. In particular, the ApoE ε4 isoform binds to Aβ 
faster than the ApoE ε3 isoform. ApoE ε4 in combination with Aβ forms monofibrils which deposit 
as dense structures of Aβ (Sanan et al., 1994). ApoE ε4 does not bind to tau in vitro whereas ApoE 
ε2 and ApoE ε3 do bind tau (Strittmatter et al., 1994). It has been speculated that interaction 
between tau protein and ApoE ε3 could protect against tau phosphorylation and NFT formation 
(Strittmatter et al., 1994). However, the exact mechanisms by which the ApoE isoforms can mediate 
their effects in the neuropathogenesis are still poorly understood. It is possible that ApoE ε4 
mediates the risk for AD via its effects on cardiovascular disease, e.g. by increasing a carrier's risk 
for suffering hypercholesterolemia (Poirier, 2000).  
In 1991 the chromosomal region of APOE on chromosome 19 was indicated in linkage analyses of 
AD families (Olaisen et al., 1982). Four years later, Lusis and colleagues succeeded in identifying 
the locus on the long arm of chromosome 19 (Table 3) (Lusis et al., 1986). Later, when Aβ had 
been shown to be bound to ApoE (Strittmatter et al., 1993), numerous researchers demonstrated an 
association of APOE ε4 allele with late –onset and sporadic forms of AD (Strittmatter et al., 1993; 
Farrer et al., 1997; Saunders et al., 2003). The association with the EOFAD is weak but some 
researchers have reported that the APOE ε4 allele may influence the age of onset in EOFAD cases 
carrying certain PSEN1 or APP mutations (Levy-Lahad et al., 1995; Nacmias et al., 1995). 
The presence of the ε4 allele is neither necessary nor sufficient to cause the disease. It act as more a 
genetic risk modifier in an interaction or co-operation with other genetic and/or environmental 
factors. The APOE ε4 allele modifies the age of onset and the presence of the ε4 allele is associated 
with AD risk. Its importance as a risk factor for the disease development is dose, age and ethnicity 
dependent (Corder et al., 1993; Farrer et al., 1997). Corder et al. showed that the risk for AD 
increases from 20 to 90% and the mean age of the LOAD decreases from 84 to 68 years with 
increasing numbers of ε4 alleles (Corder et al., 1993). While the impact of the APOE ε4 allele as a 
risk factor for disease development is evident in people from 40 to 90 years, it becomes weaker 
after the age of 75 years (Slooter et al., 1998). Generally the increased relative risk (as odds ratio, 
OR) is three fold for heterozygous and even 15 fold for the homozygous carriers of ε4 allele 
compared to ε3 homozygotes. The highest risk estimates have been found in Japanese population 
being 33- fold for ε4 homozygous subjects (Farrer et al., 1997) and lowest in Hispanics (only a two 
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fold risk) (Tang et al., 1996). Interestingly, in some African populations, APOE ε4 has not been 
associated with AD (Osuntokun et al., 1995). It is still uncertain whether these results are due to 
lower life expectancy or involvement of other environmental factors in African populations (Tang 
et al., 1996; Stewart et al., 2001).  
The reports concerning the impact of APOE ε4 allele on the mortality in the general population and 
in AD patients have been contradictorary (Corder et al., 1995; Growdon et al., 1996; Stern et al., 
1997; Craft et al., 1998; Slooter et al., 1999a; Fillenbaum et al., 2002; Lane et al., 2003). While 
Stern et al reported a slower deterioration and decreased risk of mortality in AD patients carrying ε4 
allele compared to subjects without any ε4 alleles (Stern et al., 1997) other studies have indicated 
that APOE ε4 homozygosity was associated with increased deterioration of cognitive function 
(Craft et al., 1998) and mortality (Corder et al., 1995; Olichney et al., 1997; Tilvis et al., 1998; Dal 
Forno et al., 2002). However, some studies have failed to find any clear association between ApoE 
status, disease progression or mortality rate (Growdon et al., 1996; Slooter et al., 1999b; Fillenbaum 
et al., 2002). The mortality risk related to the APOE genotype appears to be age dependent, being 
less important or non-significant in the older age groups in European (people over 65 years) and 
Afro-American (people over 75 years) populations (Lane et al., 2003; Ewbank, 2004). The expected 
life span is generally lower in men than in women. With respect to AD, similar results have been 
found i.e., longer survival in woman after the disease diagnosis has been reported independently of 
ApoE status (Corder et al., 1995) whereas in other studies the presence of APOE ε4 associated with 
poor survival in men but not in women with AD (Dal Forno et al., 2002) but there are reports that 
neither APOE genotype nor gender have any influence on the progression of the disease (Growdon 
et al., 1996). 
2.4.3 Candidate susceptibility genes for LOAD 
2.4.3.1. Positional canditate genes  
By the year 2005, almost 100 candidate AD genes had been analyzed but mostly without 
convincing evidence to claim an  association with the disease risk (Bertram and Tanzi, 2004a). As 
discussed before, in complex diseases like in LOAD, there are several difficulties in identifying and 
replicating those genetic factors which cause only moderate or small effecs. Nevertheless, on the 
basis of full genome screens (used either linkage or association method), there are a number of 
positional candidate genes that have been linked with AD at a P-value ≤ 0.01 or a lod score ≥ 1.4 by 
at least two independent groups (Bertram and Tanzi, 2004a). Some of them are also biological 
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candidate genes for AD. In addition to the locus for APOE in chromosome 19q13, these studies  
have pointed to linkage with eight other different chromosomes (Table 4) with the most promising 
loci being located on chromosomes 9,10 and 12.  
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Table 4. Linkage or association regions for positional canditate genes according to published full 
genome screens modified according to Bertram and Tanzi (Bertram and Tanzi, 2004a) 
Chromosome Study method References 
1p36 linkage 
association 
 
Myers et al 2002 
Hiltunen et al 2001 
4q35 linkage 
linkage 
 
Li et al., 2002 
Blacker et al 2003 
5p13-15 linkage 
linkage 
linkage 
association 
 
Myers et al 2002 
Pericak-Vance et al 2000 
Blacker et al 2003 
Hiltunen et al 2001 
6p21 linkage 
linkage 
association 
 
Kehoe et al., 1999 
Blacker et al 2003 
Hiltunen et al 2001 
 
6q15 linkage 
linkage 
Pericak-Vance et al 1997 
Myers et al 2002 
 
9p21 linkage 
linkage 
Pericak-Vance et al 2000 
Myers et al 2002 
 
9q22 linkage 
linkage 
association 
Kehoe et al 1999 
Blacker et al 2003 
Bertram et al., 2005  
 
10q21-22 linkage 
linkage 
 
Myers et al 2002 
Blacker et al 2003 
10q24-25 linkage 
linkage 
 
Li et al 2002 
Blacker et al 2003 
12p11 linkage 
linkage 
Pericak-Vance et al 1997 
Myers et al 2002 
 
19q13 linkage 
linkage 
linkage 
linkage 
association 
 
Pericak-Vance et al 2000 
Kehoe et al 1999 
Li et al 2002 
Blacker et al 2003 
Zubenko et al 1998 
Xp21 linkage 
linkage 
 
Kehoe et al 1999 
Blacker et al 2003 
Xp21-26 linkage 
association 
 
Kehoe et al 1999 
Zubenko et al., 1998 
 
All these reported findings have a P-value≤ 0.01 or two/multi point lod score ≥ 1.4 at least in two 
independent study. 
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Today, two genes on chromosome 9 have been associated to AD, either to disease risk or to onset 
age of AD. A Japanese group found in a case-control study, a significant association to AD with a 
polymorphism of the gene encoding for the very low density lipoprotein receptor (VLDR-R) in 
subjects carrying at least one APOE ε4 allele (Okuizumi et al., 1995). It is located in the 
neighbourhood of the signal peak observed in the linkage analyses (9p21) (Pericak-Vance et al., 
2000). This VLDR-R polymorphism association has been replicated by another Japanese group and 
association has been seen also in Caucasian Europeans (or in Caucasians originating from Europe), 
but not commonly not in the patients from other ethnic populations (Okuizumi et al., 1995; 
Pritchard et al., 1996; Helbecque et al., 1998; Yamanaka et al., 1998). Further studies are needed to 
clarify whether VLDR-R is responsible for the linkage seen on chr 9p21. The gene encoding 
ubiquilin 1 (UBQLN1) is one of candidate genes for AD located near to a linkage peak on 
chromosome 9q22. Recent findings suggest that genetic variants in UBQLN1 gene significantly 
increase the risk of AD (Bertram et al., 2005) Furthermore, another gene (ATP-binding cassette 
transporter A1, ABCA1) on chromosome 9 has been associated with onset age in AD and central 
nervous system cholesterol homeostasis in both a single allele (9q31.3) and haplotype association 
analyses, but this finding has not been confirmed in other studies (Wollmer et al., 2003; Katzov et 
al., 2004; Li et al., 2004b). A heavy cellular cholesterol load promotes Aβ formation and the ATP-
binding cassette transporter A1 (ABCA1) mediates cholesterol efflux from cells. Genetic variability 
in ABCA1 may influence cholesterol metabolism in the central nervous system (CNS) and, thus, 
impact on the development of AD (Wollmer et al., 2003).  
Recent findings from full genome screens and other studies indicate strong linkage of 10q with 
LOAD. Regions of interest derived from linkage analyses are 10q21-22 and 10q24-25 (Ertekin-
Taner et al., 2000; Myers et al., 2000). It remains unclear whether these two linkage peaks represent 
an association to one or two underlying loci. Numerous genes have been mapped on these 
cromosomal regions. Most interesting, since it is also a plausible biological candidate for AD, is the 
IDE located on 10q23-25 (Bertram  and Tanzi, 2004b). In addition to degrading insulin, IDE has a 
central role in the degradation and clearance of Aβ secreted by microglial cells and neurons 
(Vekrellis et al., 2000). Hippocampal IDE mRNA levels are lower on average in subjects with an 
APOE ε4 allele. This suggests that the genetic risk conferred by the APOE ε4 allele may be 
mediated in part by this allele's effect on IDE activity toward Aβ. It has been claimed that for the 
subjects not carrying ε4 allele, other factors which influence IDE may be relevant. One possible 
factor might be insulin which is a competitive inhibitor of IDE activity to Aβ (Edland, 2004). To 
date, several studies have succeeded in finding linkage between the genetic area consisting of IDE 
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and LOAD (Bertram et al., 2000b; Prince et al., 2003; Ertekin-Taner et al., 2004; Lee et al., 2004) 
but also opposite results have been published from  a Japanese study (Sakai et al., 2004). The 
linkage of urokinase-type plasminogen activator gene (PLAU) mapped to chromosome 10q22.2 
with LOAD has been reported though not consistently (Finckh et al., 2003; Bertram  and Tanzi, 
2004b; Papassotiropoulos et al., 2005). Urokinase-type plasminogen activator (uPA) converts 
plasminogen to plasmin. It modulates the cleavage of the APP and can degrade secreted and 
aggregated Aβ (Finckh et al., 2003).  
LOAD candidate gene loci were described on chromosome 12p in 1997 and 1998 by three different 
study groups (Pericak-Vance et al., 1997; Blacker et al., 1998; Liao et al., 1998). While Pericak-
Vance et al reported linkage with AD and certain loci in chr 12 (Pericak-Vance et al., 1997) Blacker 
et al (Blacker et al., 1998) focused on a pentadeletion/insertion polymorphism of the alpha-2-
macroglobulin (α2M) gene (A2M) located in the 5’splice site of exon 18 and finding an association 
with familial LOAD. The exon 24 of the A2M contains a known second polymorphism which 
evokes an amino acid substitution (GTC→ATC, p.Val1000Ile). Liao et al (Liao et al., 1998) 
detected an increased risk for AD in carriers of the homozygous genotype coding Val instead of Ile. 
These findings have been confirmed by two other groups (Gibson et al., 2000; Wang et al., 2001). 
The gene for LRP is located on chromosome 12, 50 cM distant from A2M. Several observations 
point to a role for this gene and the coded protein in the pathogenesis of AD. LRP is the main ApoE 
receptor expressed in neurons (Rebeck et al., 1993), mediating neurite outgrowth in an ApoE 
isoform-dependent manner (Holtzman et al., 1995). It is responsible for the endocytosis of secreted 
APP (Kounnas et al., 1995) and is detected in senile plaques, dystrophic neuritis and reactive 
astrocytes in AD brain (Rebeck et al., 1995).Two different LRP gene polymorphisms have been 
reported in association with AD (Kang et al., 1997; Lendon et al., 1997; Kolsch et al., 2003) but 
these reports have not been confirmed (McIlroy et al., 2001; Causevic et al., 2003). The other 
polymorphism is a silent point mutation in exon 3 of LRP gene, may reflect actually the linkage 
disequilibrium between this polymorphism and a functional variant of the LRP gene (Kang et al., 
1997). Another chromosome 12 associated gene, a biallelic polymorphism (G>A) in the 3' 
untranslated region of the transcription factor LBP-1c/CP2/LSF has been implicated in AD 
susceptibility (Lambert et al., 2000). This gene is located in the neighbourhood of the LRP gene and 
it regulates the expression of several genes such as α2M and IL1. Further research on LRP and LBP-
1c/CP2/LSF polymorphisms is needed to evaluate their effects on the risk of AD. 
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2.4.3.2 Biological candidate genes 
The most interesting positional candidate genes for AD are involved, at least theoretically, in AD 
related pathophysiological cascades are those that are also biological susceptibility genes. 
Involvement of the immune system in the pathogenesis of AD has been discussed. Specific type T 
lymphocytes and reactive microglia as well as several markers of inflammation are evident in AD 
brain (Rogers et al., 1996; Tarkowski et al., 2003). The protective effect of NSAIDs for AD has 
been demonstrated in several epidemiological studies (Stewart et al., 1997; McGeer and McGeer, 
1999). Furthermore, the involvement of vascular risk factors such as high midlife blood pressure, 
cholesterol, glucose intolerance and insulin resistance (Kuusisto et al., 1997; Breteler, 2000; Launer 
et al., 2000; Kivipelto et al., 2001a) in the etiology of AD has received considerable attention. 
These findings together with theory that different gene variations might influence the expression of 
the gene and consequently to the risk of AD  have highlighted a group of the purely biological AD 
candidate genes (without linkage evidence) such as cystatin-C (Finckh et al., 2000; Goddard et al., 
2004), cathepsin D (Kenessey et al., 1997; Sadik et al., 1999) and bleomycin hydralase (Namba et 
al., 1999) as well as the genes investigated in this study: IL-6, cholesterol 24S-hydroxylase 
(CYP46), α1-antichymotrypsin gene (SERPINA3, also the abbreviation ACT is used widely) and the 
peroxisome proliferator-activated receptor γ (PPARγ, according to HUGO nomenclature PPARG). 
The selection of these candidate genes on the basis of several published articles is presented in 
Table 5 and the genes investigated in this study are described in detail. Furthermore there are 
several studied AD susceptibility genes like IL1, which are involved in inflammatory mechanisms, 
but according to large a recent recent large meta-analysis it was more associated with EOAD rather 
than LOAD (Rainero et al., 2004).  
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Table 5. Biological candidate susceptibility genes for LOAD (Papassotiropoulos et al., 2001; Prince et al., 2001; Rocchi et al., 2003) 
Gene Chromosomal 
localization 
Studied 
polymorphisms 
Association 
in AD risk 
Protein Expression in 
CNS 
Pathophysiological 
relevance 
References 
ACE 17q23 int16 Deletion/Insertion 
(D/I)  
 +/- 
meta-anal:+ 
Angiotensin 
converting enzyme 
-Cerebral blood 
vessels-
endothelium, 
-neurons- 
supraoptic and 
paraventricular 
hypothalamic 
nuclei and basal 
forebrain and 
midbrain 
 
Unclear 
Theoretical: 
links through vascular 
disease -blood pressure 
regulation? 
inflammatory cascade?
Elkins et al., 2004  
Tian et al., 2004 
Camelo et al., 
2004 
Kehoe et al 2004 
 totally over 30 
studies 
BLMH 17q11.1-11.2 A1450G +/- Bleomycin hydralase 
(cysteine protease) 
Astrocytes A candidate for the β-
secretase 
secretion of Aβ-
peptide 
Montoya et al., 
1998  
Farrer et al., 1998 
Namba et al., 
1999 
Malherbe et al., 
2000 
BChE-
K 
3q26.1 G1615GA +/- 
or 
protection? 
Butyrylcholinesterase 
K-variant 
-Neurons 
-NFT 
-senile plaques 
Hypothetical:Wild type 
BChE-participation in 
the transformation of 
Aβ to a neurotoxic 
dense form? 
BChE-K- protects from 
increased Aβ 
formation by having 
reduced enzymatic 
activity?Or increases 
risk? 
Lehmann et al., 
1997  
Hiltunen et al., 
1998  
Wiebusch et al., 
1999  
Tilley et al., 1999  
Alvarez-Arcaya et 
al., 2000  
Mattila et al., 
2000 
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Table  5. continued      
Gene Chromosomal 
localization 
Studied 
polymorphisms 
Ass in AD 
risk 
Protein Expression in 
CNS 
pathophysiological 
relevance 
References 
CatD 11p15 exon 2 C>T +/- Cathepsin D 
(intracellular 
protease)  
-Neurons 
containing NFT 
- endosomes of 
pyramidal 
neurons 
 
Cleaves APP into 
amyloidogenic 
components,  
degrades tau protein 
secretase? 
Touitou et al., 
1994 
Cataldo et al., 
1997 
Papassotiropoulos 
et al., 1999a 
Sadik et al., 1999  
Callahan et al., 
1999 
Ingegni et al., 
2003 
CST3 20  5’flanking region 
G157C 
exon1 
G73GA 
(p.Ala73Thr) 
-73G/G age-
dependent 
+/- 
Cystatin C 
(amyloidogenic 
protein)  
Neurons 
activated glia 
mainly in 
temporal cortex 
(hippocampus, 
entorhinal 
cortex) 
(cerebral bood 
vessels , NFT) 
Extracellular inhibitor 
of cysteine proteases 
secreted by monocytes/ 
macrophages. 
Altered secretion of 
cystatin C, 
reduced rate of cystatin 
C synthesis 
Finckh et al., 2000  
Beyer et al., 2001  
Deng et al., 2001  
Goddard et al., 
2004 
 
NEP 3q25.1–q25.2 several 
polymorphic sites 
Haplotype 
analysis + 
SNP:s +/- 
Neprilycin 
(Aß degrading 
enzyme 
zinc dependent 
metallopeptidase) 
Pyramidal 
neurons, 
smooth muscle 
cells of blood 
vessels 
Aß degrading Carpentier et al., 
2002 
Clarimon et al., 
2003  
Lilius et al., 2003  
Helisalmi et al., 
2004  
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Table 5. continued      
Gene Chromosomal 
localization 
Studied 
polymorphisms 
Association 
in AD risk 
Protein Expression in 
CNS 
Pathophysiological 
relevance 
References 
NOS3 
 
7q35 A298T 
(p.Glu298Asp) 
at least 4 other 
polymorphic sites 
- 
Glu298Glu 
+/- 
others –not 
studied 
Endothelial nitric 
oxide synthase 
Cell membrane, 
cell cytosol, 
high 
concentrations in 
hippocampal 
pyramidal 
neurons 
 
increased nitric oxide 
(NO) production by 
microglial cells, 
astocytes and brain 
endothelium> NO in 
neuronal death 
stimulation of 
oxidative stress by NO 
Dahiyat et al., 
1999  
Kunugi et al., 
2000 
5-HTT 17q11.1-q12 promoter region 
deletion/insertion 
VNTR 
polymorphisms in 
2. intron 
D/I short  
variant +/- 
VNTR- not 
studied 
Serotonin transporter 
 
 
Serotonergic 
neurons?  
Involved in 
serotonergic 
neurotransmitter 
system 
short variant- reduced 
transcriptional activity 
Meltzer et al., 
1998  
Mundo et al., 
2000  
Hu et al., 2000 
Kunugi et al., 
2000  
Hranilovic et al., 
2004 
TGF-
β1 
19q13.1-13.3 G800A 
C509T 
exon 5 missense 
mutation at codon 
263  
-800 – 
-263 – 
-509 +/- 
Transforming growth 
factor -β1 
(immunosuppressive 
cytokine) 
Astrocytes -Aβ accumulation  
-Aβ clearance by 
activated microglia 
Lindholm et al., 
1992 
Luedecking et al., 
2000 
Araria-Goumidi et 
al., 2002 
Lesne et al., 2003 
Each gene written by using abbreviation, the full name of the gene is the same as the names of the protein. p. = protein, SNP = single nucleotide 
polymorphism, Aβ = β-amyloid, NFT = neurofibrillary tangle, CNS = central nervous system, + = associated with AD risk, - = association 
studied without significant findings, +/- = controversial findings in association between studied polymorphism and AD 
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IL-6 is a multifunctional inflammatory cytokine to involved in the. acute inflammatory response as 
ell as in the modulation of specific immune functions and B- and T-cell differentiation, aging, and 
bone metabolism (Papassotiropoulos et al., 2001). Furthermore, IL-6 may stimulate astrocytes to 
produce nerve growth factor (NGF) production and act by itself as neurotrophic factor in synergy 
with NGF. It mediates also neuronal degeneration (Papassotiropoulos et al., 2001; Tarkowski et al., 
2003). It has several synonyms such as interferon-β2, hepatocyte stimulatory factor and many 
others in the literature (Papassotiropoulos et al., 2001). 
Elevated IL-6 immunoreactivity has been observed in the amyloid plaques in AD patients’ brain but 
it was claimed also to be in the plaques of nondemented elderly persons. In AD patients the 
majority of IL-6 – positive plaques were diffuse (71%) while immunoreactivity was absent in 
compact plaques. This suggests that IL-6 induction may be an early event in the AD 
neurodegenerative cascade (Huell et al., 1995). Several epidemiologic studies have shown that 
onset is delayed and prevalence of AD is reduced by 40 - 50% in persons using antiinflammatory 
drugs (McGeer and McGeer, 1999). Also, in transgenic mouse models, elevated CNS levels of IL-6 
resulted in a chronic-progressive neurological disorder and a cognitive decline (Campbell et al., 
1997).  
The IL-6 has a specific receptor complex through which its functional effects are mediated. The 
complex consists of a membrane-anchored signal transducing glycoprotein gp130 (IL-6ST) and 
membrane-anchored ligand binding glycoprotein gp80 (IL-6R). Moreover, soluble forms of the 
ligand binding glycoprotein gp80 (sIL-6R) and the signal transducing glycoprotein gp130 (IL-6ST) 
binds to and are involved in IL-6 signaling. In contrast, an antagonistic mechanism has been 
proposed for gp130, which blocks IL-6 function (Papassotiropoulos et al., 2001). 
The accumulation and aggregation of the Aß in the brain are crucial factors contributing to AD. 
Consequently, preventing the generation of Aß is an important preventive and therapeutic strategy. 
Recent work on the metabolism of Aß has identified several cellular proteins and proteases that 
collectively promote or prevent the generation of Aß. In addition, accumulating in vitro and in vivo 
evidence points to a role of cholesterol in modulating the cellular processing of Aß (Sparks et al., 
1994) and there is clinical data to support its role in AD risk (Jarvik et al., 1995; Kivipelto et al., 
2001b). A major portion of brain cholesterol is thought to be converted to soluble 24(S)-
hydroxycholesterol which can diffuse across the blood brain barrier (BBB) entering into the 
cerebral circulation (Raffai and Weisgraber, 2003). Bodowitz and Klein (Bodovitz and Klein, 1996) 
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showed that plasma membrane cholesterol levels modulate APP processing via the α-secretase 
pathway in vitro. A Cholesterol-extraction agent or statin treated neuronal and non -neuronal cell 
lines exhibited increased α-secretase activity and the release of the soluble APP splicing products 
with decreased β-secretase activity.  
Cyp46 plays a key role in the hydroxylation of brain cholesterol and regulates the elimination of 
brain cholesterol into plasma across the blood brain barrier (Bodovitz and Klein, 1996; Lund et al., 
1999; Raffai and Weisgraber, 2003). It belongs to the sub -family of the cytochrome P450 enxymes 
and in humans it is highly expressed in the brain messenger RNA. In mouse brain, it has been found 
especially in neurons of the hippocampus, cerebral cortex and dentate gyrus, the areas vulnerable in 
AD pathogenesis. Therefore, functional alterations of Cyp 46 could modulate cholesterol 
concentrations in neurons and associated changes in APP processing and in Aβ production 
(Papassotiropoulos et al., 2003).  
One of proteins involved in inflammatory reactions to be associated with AD brain lesions is α1-
antichymotrypsin (ACT), an acute phase proteinase inhibitor of the serpin family(Abraham, 2001). 
ACT is one of the components of senile plaques where it binds Aβ with high affinity (Abraham et 
al., 1990) and pathological expression of ACT occurs in astrocytes in areas that develop amyloid 
lesions (Abraham, 2001). ACT synthesis is induced in cultured human astrocytes by IL1. IL1 is a 
lymphokine, the expression of which is up-regulated in microglial cells from affected areas of AD 
brain (Das and Potter, 1995). Furthermore, ACT and IL1 expression by microglia and astrocytes 
respectively showed a regional different distribution of expression occuring spontaneously on 
cortex (Das and Potter, 1995). Furthermore, AD patients with the APOE ε4 allele exhibited 
increased levels of ACT and an increased number of diffuse microglia positive cells (Cheng et al., 
2002). In summary, in amyloid deposits ACT is found only in association with Aβ. ACT may have 
a role in the processing of β-APP or it stabilizes Aβ deposits. ACT levels have been significantly 
higher in AD patients compared to controls (Harigaya et al., 1995), their levels increasing in 
advanced stages of the disease (Matsubara et al., 1990). 
Some “classical” and widely used NSAIDs such as indomethacin and ibuprofen are able to activite 
the PPARγ and this has been reported to inhibit the expression of a wide range of proinflammatory 
genes (Landreth and Heneka, 2001). This observation is supported by a re-analysis of the above 
mentioned epidemiological studies in which the reduced risk of AD correlated to the usage of this 
subset (e.g. ibuprofen and indomethacin) of Aβ lowering NSAIDs and, also the results from in vitro 
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and experimental animal studies showing the decreased Aβ production independently of COX-
inhibition after treatment with unselective NSAIDs (Weggen et al., 2001; van Gool et al., 2003). 
PPARs have ligand and DNA binding domains. They belong to the nuclear receptor super family of 
DNA-binding transcription factors whose transcriptional regulatory actions are activated after 
ligand binding. Activated PPARs form a heterodimeric complex with another nuclear receptor, the 
retinoic X receptor, and bind to certain PPAR response elements in the promoters of specific target 
genes and thus they are able to regulate their expression, either inducing or suppressing the 
transcriptional activity of the target gene (Plutzky, 2003) (Figure 3).  There are three PPAR 
isoforms termed PPAR α, β, and γ. They are differentially expressed. The natural ligands for 
PPARs are fatty acids and lipid metabolites. Furthermore, each PPAR isoform has its own specific 
ligands (Combs et al., 2000). 
 
 
 
 
 
 
 
 
Figure 3. PPAR as transcription factor. PPARs control gene expression through a heterodimeric 
complex with retinoid X nuclear receptor (RXR). The activation of these receptors are controlled by 
binding of specific ligands (L). Furthermore, the transcriptional response is determined by the 
association or release of specific coactivators and corepressors. The formed complex binds to PPAR 
response elements (PPRE) in the promoter regions of target genes to modulate their expression 
(modified according to Pluzky, 2003). 
 
L L
PPAR RXR
Coactivators Corepressors
PPRE Gene
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PPARγ is expressed in fibroblasts, adipose cells, lymphocytes including B cells, in the major 
cellular constituents of vessel wall (endothelial cell, vascular smooth muscle cell, monocytes and 
macrophages), and in atherosclerotic lesions. PPARγ regulates adipogenesis and insulin sensitivity 
as well as lipid metabolism target genes, e.g. apolipoprotein A-1 and lipoprotein lipase which are a 
key mediators in metabolic syndromes such as diabetes and obesity. Recent studies suggest that 
some PPARγ mutations found in humans may result in severe insulin resistance and hypertension 
(Plutzky, 2003).  
There is evidence that PPARγ also regulates the expression of other genes involved in a variety of 
other physiological functions (Willson et al., 2000; Landreth and Heneka, 2001; Willson et al., 
2001) such as the regulation in lipid and carbohydrate metabolism (Willson et al., 2000; Willson et 
al., 2001). It is also implicated in atherosclerosis (Tontonoz et al., 1998).  
The PPAR γ isoform has recently been found to be expressed in Aβ stimulated monocytes and 
macrophages. The principal function of PPARγ in these inflammatory cells is to suppress the 
expression of the proinflammatory cytokines IL1β, TNFα, IL-6 and other proinflammatory 
products. Simultaneously, decreased secretion of  these products blocks astrocyte proliferation 
(Combs et al., 2000). In cell cultures, the J class prostaglandin PGJ2 (Kliewer and Willson, 1998) 
and, interestingly, also NSAIDs (Combs et al., 2000) and thiazolidinedione class antidiabetic drugs 
(Combs et al., 2000) functioning as PPARγ agonists can inhibit before mentioned Aβ stimulated 
secretion of proinflammatory products preventing microglial (mouse cells) and monocyte (human 
cells) mediated neurotoxicity (Combs et al., 2000) Furthermore, incubation of microglia with 
troglitazone inhibited the Aβ-mediated COX-2 immunoreactivity. 
Furthermore, PPARγ  may influence directly the neuroinflammatory responses seen in brain 
(Landreth and Heneka, 2001). Recently, Sastre et al. demonstrated that PPARγ reduction 
potentiated β-site amyloid precursor protein (APP) cleaving enzyme (BACE1) mRNA levels by 
increasing BACE1 gene promoter activity (Sastre et al., 2006). This indicates that an increase of 
PPARγ activity could inhibit the activity of BACE1 They also found and localized a PPARγ 
responsive element (PPRE) in the BACE1 gene promoter (Sastre et al., 2006). In conjunction with 
previous findings, this indicates that PPARγ may play a critical role in regulating the inflammatory 
responses of microglia and monocytes related to beta-amyloid i.e. PPARγ is involved in AD 
pathogenensis via its ability to interfere with inflammation (Combs et al., 2000; Sastre et al., 2006). 
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2.4.3.3. Interleukin-6 (IL-6) polymorphism 
The gene coding for IL-6 found in the short arm of chromosome 7 (7p21) contains five exons and 
four introns. Several transcription factors such as nuclear factor IL-6 or activator protein-1 (AP-1) 
mediate the activation of the IL-6 promoter while steroids result in inhibition of the activity of the 
IL-6 promoter.  
Two of several polymorphic sites have been used for genetic association studies: A biallelic G174C 
promoter polymorphism (according to Nomenclature Guidelines IL6 c.174G>C) and a multiallelic 
variable number of tandem repeats (VNTR; having AT repeats) polymorphism in the 3’ flanking 
region of IL-6. The associations with several conditions and diseases have been studied. At least 
two independent studies have revealed an association between G174C polymorphism and bone 
mineral density, plasma IL-6 levels (also in AD patients) and the regulation of IL-6 transcription 
(Fishman et al., 1998; Papassotiropoulos et al., 2001; Capurso et al., 2004). Interestingly, 
considering the possible pathophysiological mechanisms involved in AD, a positive association 
with this polymorphism and lipid metabolism, atherosclerosis as well as with type II diabetes has 
been detected. The VNTR polymorphism is not as well confirmed in association with other diseases 
but there is at least one positive finding relating this polymorphism to other diseases 
(Papassotiropoulos et al., 2001). 
The results from studies defining the AD risk associated with the IL-6 single nucleotide 
polymorphisms are highly controversial (Bagli et al., 2000; Bhojak et al., 2000; Pola et al., 2002; 
Shibata et al., 2002; Faltraco et al., 2003; Licastro et al., 2003; Arosio et al., 2004; Capurso et al., 
2004; Depboylu et al., 2004; Nishimura et al., 2004; Zhang et al., 2004). Most of them have 
investigated G174C promoter region polymorphism in association with the LOAD risk. Licastro et 
al postulated that the C- allele of the IL-6 promoter region polymorphism increases the disease risk 
(Licastro et al., 2003; Capurso et al., 2004). Furthermore, Licastro et al found an increased level of 
IL-6 in the blood and brain in those subjects with the CC genotype. In contrast, other studies have 
suggested that it is the G allele (Shibata et al., 2002) or GG genotype (Pola et al., 2002) which 
associate with increased AD risk. to further to confuse the situation, Faltraco et al reported 
decreased disease risk in individuals with the C- allele (Faltraco et al., 2003). Finally, six other 
studies failed to find any association between this IL-6 promoter region polymorphism and AD 
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(Bagli et al., 2000; Bhojak et al., 2000; Capurso et al., 2004; Depboylu et al., 2004; Nishimura et 
al., 2004; Zhang et al., 2004).  
Papassotiropoulos et al found in 1999 for the first time an association between IL-6 VNTR 
polymorphism and LOAD risk, claiming a protective effect for the VNTR C allele. The C allele 
carriers had delayed disease onset and their risk of AD was reduced (Papassotiropoulos et al., 
1999b). This association has been confirmed later by Licastro et al (Licastro et al., 2003) who 
reported also increased blood IL-6 levels in the VNTR polymorphism DD genotype carriers 
(Licastro et al., 2003) whereas Shibata did not find any association with this polymorphism and AD 
(Shibata et al., 2002). The reasons for these highly conflicting results have been discussed. Capurso 
et al reviewed the German and Italian studies and concluded that geographical background might 
explain some of the discrepant findings on IL-6 polymorphism in AD. They noted that in these 
European populations, the frequency of G allele increases as one moves towards the southern parts 
of the continent (Capurso et al., 2004).  
Interestingly, the only published haplotype analysis showed a strong linkage disequilibrium 
between IL-6vntr and IL-6prom, demonstrating an association between the IL-6vntr C allele and IL-
6prom C allele combination and reduced AD risk (Bagli et al., 2000). 
2.4.3.4. Cholesterol 24 -hydroxylase (CYP46) polymorphism 
The Cyp46 is encoded by the cholesterol 24-hydroxylase gene (CYP46) on chromosome 14q32.1 
(Raffai and Weisgraber, 2003), in the neighbourhood of the SERPIN A3 (also called ACT, encoding 
α1-antichymotrypsin which is a serine proteinase inhibitor, an acute phase protein). The encoding 
area of CYP46 consists of 15 exons (Papassotiropoulos et al., 2003).  
Some groups have reported significant associations with different CYP46 polymorphisms (Kolsch 
et al., 2002; Papassotiropoulos et al., 2003; Borroni et al., 2004; Combarros et al., 2004; Johansson 
et al., 2004; Wang et al., 2004). By using an intronic SNP(Reverse rs754203 predicts a T>C 
substitution in intron two according to their report, but according to the genomic sequence of the 
CYP46 gene, http://genome.ucsc.edu, designation of the forward rs754203 SNP is A>G) 
Papassotiropoulos et al reported an association between T- homozygosity and increased Aβ load, 
increased CSF levels of Aβ and phosphorylated tau protein (Papassotiropoulos et al., 2003). 
Furthermore, this CYP46 polymorphism was significantly associated with increased LOAD risk in 
subjects having two T-alleles compared to C-allele carriers in two independent populations (OR 
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2.16). The presence of the APOE ε4 allele synergistically with the TT genotype increased the 
LOAD risk to an OR of 9.6 which was a two fold greater risk than that attributable to the ε4 allele 
alone (Papassotiropoulos et al., 2003). Previously Kölch et al (Kolsch et al., 2002) had found 
another SNP in intron 3 ( rs4900442: C>T substitution ) and shown that the C-allele at this locus is 
more frequent among LOAD patients. Moreover, CC genotype carriers had a significantly higher 
24S-hydroxycholesterol/cholesterol ratio and total cholesterol of CSF compared to the T-carriers. 
the association of Intron 2 polymorphism with AD risk has been reported by later at least three 
independent groups (Borroni et al., 2004; Combarros et al., 2004; Wang et al., 2004). However, two 
of them reported that the increased AD risk was associated with the C-allele (Forward: G-allele). 
Borroni et al found a 2.8 fold AD risk for C-carriers; those subjects having both CYP46 allele and 
APOE ε4 allele had an almost 18 fold increased risk to develop AD demonstrating their synergistic 
effect on AD risk while the risk attributable to the APOE ε4 allele was 4.1 fold (Borroni et al., 
2004). Combarros et al claimed that intron 2 CYP46 C/C (corrected G/G) genotype predisposed to 
the development of AD, with the association being independent of the APOE genotype (Combarros 
et al., 2004). Meanwhile, Johansson et al could not confirm the previous findings related to AD risk 
and intron 2 polymorphism, but noted that AA (CC in Papassotitopoulos study) homozygous 
LOAD patients carrying APOE ε4 allele had elevated Aβ concentrations in CSF compared to G- 
carriers in these stratified groups (Johansson et al., 2004). Their findings are in contrast with the 
findings reported by Papassotiropoulos (Papassotiropoulos et al., 2003; Johansson et al., 2004). 
Other workers have not found any association between intron 2 polymorphism and AD risk (Desai 
et al., 2002; Ingelsson et al., 2004). Furthermore, Ingelsson et al (Ingelsson et al., 2004) did not find 
increase in the brain levels of Aβ40, Aβ42 or in the levels of amyloid plaques or NFT.  
2.4.3.5. SERPINA3 
The gene encoding α-1-antichymotrypsin (SERPINA3, abbreviation ACT used also widely) is 
located ~5.5 cM 3’ to the CYP46 gene on chromosome 14q32.1. The gene harbours several 
polymorphic sites which are associated with either an increased or decreased risk to AD as well as 
the age of onset or plasma ACT concentration depending on the SNP (Kamboh et al., 1995; Meng 
et al., 2000; Wang et al., 2002).  
 2.4.3.6. The peroxisome proliferator-activated receptor γ (PPARγ) polymorphism 
PPARγ gene is located on chromosome 3p25 (Beamer et al., 1997) including nine exons (A1, A2, B 
and exons1-6) spanning about 100 kb. Alternate transcription start sites and splicing generate four 
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PPARγ1, γ2, γ3 and γ4 mRNA isoforms (Meirhaeghe and Amouyel, 2004). PPARγ1, γ3 and γ4 
encode the same protein product (Meirhaeghe and Amouyel, 2004). PPARγ1 is encoded by seven 
exons. The 5’-untranslated sequence of PPARγ1 is encoded by exons A1 and A2. Instead, the 5’-
untranslated sequence of PPARγ2 and 28 amino acids containing a unique N- terminal, are encoded 
by exon B which is located between exons A1 and A2. The other six exons are shared at least by 
both PPARγ1 and PPARγ2 (Fajas et al., 1997) (Figure 4). PPARγ2 and PPARγ3 are predominantly 
expressed in adipose tissue whereas PPARγ1 is expressed in a wide variety of tissues. The 
expression pattern of PPARγ4 remains to be clarified.  
 
 
 
 
 
 
Figure 4. Organization of human PPARγ genes. Exons are represented by black and gray rectangles 
and introns by lines. Exons 1-6 are common for both PPARγ1 and PPARγ2. Exons A1 and A2 of 
PPARγ1 and Exon B (existing between A and B) of PPARγ2 are represented separately (modified 
according to Fajas et al., 1997). 
Rare mutations of PPARγ have been described in a few individuals, leading to a complex phenotype 
called “PPARγ ligand resistence (PLR) syndrome” with partial lipodystrophy, severe insulin 
resistance, type 2 diabetes, dyslipidemia, hypertension, and hepatic steatosis (Meirhaeghe and 
Amouyel, 2004). Common polymorphisms of PPARγ are quite frequent and they appear to have a 
significant impact on general health (Meirhaeghe and Amouyel, 2004). Most studies are related to 
the exon B specific Pro12Ala polymorphism (the c.12C>G variant predicting the substitution of Ala 
for Pro in position 12 of exon B) but some studies have also focussed on the silent single nucleotide 
polymorphism C478T (according to Nomenclatuere Guidelines c.478C>T) and C1431T (according 
to Nomenclatuere Guidelines c.1431C>T) in exon 6. 
A1A2 B 1 2 3 4 5 6
hPPARγ
γ1 γ2
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The PPARγ Pro12 Ala substitution was identified in 1997 by Yen and colleagues (Yen et al., 1997) 
after which numerous studies have been published on the impact of the Pro12Ala polymorphism 
and various diseases. The frequency of the rare Ala allele varies depending on ethnicity being 
lowest in Africans and Asians (1-3%) and highest (20%) in some Caucasian populations being 13% 
in the Finnish population (Valve et al., 1999). While the Ala12 allele has been associated most 
frequently with protection against type 2 diabetes and myocardial infarction, improved insulin 
sensitivity and lower BMI also conflicting results exist as well as reports from studies which did not 
find any association between Pro12Ala allele and these diseases (Deeb et al., 1998; Tontonoz et al., 
1998; Valve et al., 1999; Meirhaeghe and Amouyel, 2004). Furthermore, in vitro studies have 
detected differences in binding affinity and transactivation of PPARγ Pro12Ala variants (Deeb et 
al., 1998). The Ala isoform displayed a two-fold lower affinity for its PPAR response element 
(PPRE) and reduced ability to transactivate responsive promoters (Deeb et al., 1998). The decreased 
activity of the PPARγ in 12Ala allele carriers has been confirmed in subsequent in vitro and in vivo 
studies (Koch et al., 1999; Masugi et al., 2000; Stumvoll et al., 2001; Schneider et al., 2002).  
In 1998 Meirhaege et al published an association study of silent exon 6 1431T allele with leptin 
levels (Meirhaeghe et al., 1998). They reported that in obese T allele carriers, for a given leptin 
level, the BMI was lower than expected, assuming that the relationship between BMI and plasma 
leptin levels was related to the studied polymorphism (Meirhaeghe et al., 1998). Valve et al have 
shown that 478T homozygous obese women have greatly increased body fat-mass compared to C-
carrier obese women (Valve et al., 1999). Since these polymorphisms are “silent”, the protein they 
code does not change. One has to consider whether these single nucleotide polymorphisms (SNP) 
reflect another real disease predisposing factor nearby or do they really have some impact on the 
functions, e.g., on the stability of the coded protein. Theoretically, PPARγ gene polymorphism 
might influence the expression, activity or ligand binding affinity of the PPARγ protein and 
consequently interfere with the PPARγ mediated reactions in brain and inthis way modify the AD 
risk (Kliewer and Willson, 1998; Combs et al., 2000). In the only reported study, no significant 
findings were noted between Pro12Ala PPARγ polymorphism and AD risk (Sauder et al., 2005). 
However, interestingly, that study revealed that AD patients carrying the Ala allele had higher 
plasma 24S- hydroxycholesterol/ cholesterol ratios compared to homozygote Pro- allele carriers 
(Sauder et al., 2005). The influence of the other variations in the PPARγ gene on the AD risk, 
disease onset or course remains to be clarified. 
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3. AIMS OF THE STUDY 
This study is part of an ongoing project intending to search for novel risk genes for AD in the 
relatively homogenous Finnish population. Despite the well established effects of the APP, PSEN1, 
PSEN2 and APOE genes in EOAD and LOAD, it is evident that additional susceptibility genes are 
involved in the underlying disease process. Based on the results from pathophysiological studies, 
four biological candidate susceptibility genes were selected for association studies in order to 
identify novel gene loci involved in AD, especially with LOAD. Furthermore the survival of the 
AD patients compared to controls and the effect of APOE and gender to survival in AD patients was 
examined 
The specific aims of the study were: 
1) To determine whether the survival is influenced by the ApoE ε4 phenotype, the presence of AD 
or gender in the aged Finnish population. Additionally, to investigate whether there are any gender 
and ApoE ε4 phenotype related differences in the survival in LOAD patients (Study I). 
2) To investigate the previously described IL-6 association with LOAD risk in our population based 
sample of aged Eastern Finnish subjects (Study II). 
3) To test the hypothesis whether the CYP46 gene associates with AD in age matched late-onset AD 
subjects and controls. Furthermore, due to the chromosomal proximity of CYP46 and SERPINA3 
genes, the SERPINA3 gene was also examined in relation to the AD risk (Study III). 
4) To examine whether the PPARγ is involved in the risk or age of onset of LOAD in Finnish 
population (Study IV). 
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4. SUBJECTS AND METHODS  
4.1. Subjects 
Studies I, II and IV were carried out in a population based sample of aged subjects (living in 
Kuopio, Finland) in the Departments of Neurology and Medicine, University of Kuopio and Kuopio 
University Hospital. Study III was carried out in a sample of aged Eastern Finnish patients and age 
matced controls and conducted by the Department of Neurology in University of Kuopio and 
Kuopio University Hospital (study III). All of these experiments and analyses used for population 
based studies I, II and IV were carried out between 1986 and 2003.  Study III was performed in 
2004, comparing cases and controls and is part of the larger genetic study. The studies were 
approved by the Ethics Committee of the University of Kuopio and Kuopio University Hospital. All 
participants provided informed consent. In those cases when the patient was incompetent, the 
caregiver signed the consent form.  
The study included four different samples (three of them based on the same original study 
population) of subjects. More women than men participated in these studies but the frequency of 
females was equal in both AD and control groups (Table 6). Generally the AD patients were 
slightly older and in studies I, II and IV less educated and had lower Mini-Mental State examination 
(MMSE) scores compared to the controls (all P≤0.02). The ApoE ε4 (in study IV APOE ε4) allele 
was significantly more common in AD patients (p<0.001). Demographic data concerning the AD 
patients and control subjects used in these studies are indicated in Table 6. 
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Table 6. Demographic data of the AD patients and controls.  
 Study I Study II Study III Study IV 
 AD CO AD CO AD CO AD CO 
Number of subjects 48 1251 65 542 422 469 125 461 
Gender             M/F 16/32 455/796 18/47 194/348 293/129 284/185 32/93 170/291 
Age  
             years (range) 
70±3* 
(65-74) 
69±3 
(65-74) 
78 ± 3 * 
(72-82) 
76±3 
(72-83) 
72±7* 
(43-90) 
70±5 
(60-87) 
77±3 
(72-82) 
76±3* 
(72-83) 
Education 
             years (range) 
5±2* 
(0-10) 
7±4 
(0-21) 
5±2 * 
(0-12) 
7±4 
(0-21) 
- - 6±3 
(0-20) 
7±4 
(0-21) 
ApoE4+ 
         N (percentage) 
27** 
 
(56 %) 
393 
 
(32 %) 
37** 
(56 %) 
151¹ 
(28 %) 
311** 
(74 %) 
129 
(28 %) 
69** 
(55%) 
113¹ 
(25%) 
Gluc            mmol/L - - 6.8±2.6* 6.1±1.7 -  6.5±2.2* 6.1±1.8 
Ins               mmol/L - - 19.6±13.2* 15.3±8.1 -  18.4±11.8* 15.4±8.0- 
TC               mmol/L - - 6.4±1.1 6.6±1.3 -  6.5±1.2 6.6±1.3 
HDL-C        mmol/L - - 1.3±0.3 1.3±0.3 -  1.3±0.3 1.3±0.3 
LDL-C        mmol/L -  4.2±1.1 4.5±1.1 -  4.3±1.1 4.5±1.2 
Trigly          mmol/L - - 1.9±1.0 1.8±0.9 -  2.0±1.1 1.8±0.8 
SBP               mmHg - - 162±25* 155±23 -  160±23* 154±23 
DBP              mmHg - - 81±10 81±10   81±10 82±10 
The results are given as number of subjects (N) or as means ± standard deviation. Study I Age at the first clinical examination. Study II and IV age at the last cognitive 
examination in 1994. Study III Age at the cognitive screening for controls and age of onset for AD subjects. AD = Alzheimer’s disease patients; CO = controls; M/F= male/ 
female; ApoE4+= number and (percentage) of apolipoprotein E ε4 allele carriers, one or two alleles; Gluc= glucose;Ins= insulin; TC= total cholesterol; HDL-C= high –
density lipoprotein cholesterol; LDL-C= low –density lipoprotein cholesterol; Trigly= triglycerides; SBP =  systolic blood pressure; DBP= diastolic blood pressure; All the 
laboratory values measured in 1986-88 at first study visit after 12 hours of fasting.¹ ApoE status for three controls were missing in studies II and IV.* P≤ 0.02 in univariate 
tests (t-test and Mann Whitney), AD patients compared to controls. ** P< 0.001 in Pearson χ² test, AD patient compared to controls.
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Studies I, II and IV 
Table 7. Crucial interventions and formation of the study population during follow-up.    
Year  Intervention Number of invited or 
evaluated subjects 
AD  
subjects 
Controls
1986 Invitation letter 1910  - - 
1986-88  First clinical examination, 
laboratory tests 
1299 - - 
1990-91  First neurological 
examination, DNA sample 
980 examined  and 319 
evaluated using medical records 
48¹ 1251² 
1993-94  Third neurological 
examination 
632 65 ³ 5424 
1995 Checking of survival 1299 48¹ 1251² 
1997 Checking of survival 48 48¹  
2003  Checking dementia 
diagnoses  
1299 125³ 4614 
¹Number of identified AD subjects in 1990-91 and used as cases in the study I. ²Number of controls 
for the study I. ³Number of identified AD subjects since 1986 who gave also a DNA sample. 
4Number of eligible non-demented controls with DNA sample for the study II and IV. 
 
The subjects in studies I, II and IV had originally participated in a larger follow-up study launched 
in 1986. At that time, a cohort of 1910 subjects, aged 65-74 years, was randomly drawn from the 
register of eastern Finnish city of Kuopio and sent a letter inviting them to participate in the study. 
A total of 1299 of them responded to the postal questionnaire and participated in the first clinical 
evaluation. They represented totally 25 % of all subjects in that age group living in this area. First 
the evaluation of risk factors and prevalence of cardiovascular disorders was carried out in 1986-
1988 in the Department of Medicine, University of Kuopio (Mykkanen et al., 1990; Kuusisto et al., 
1997). The values (blood pressure, fasting glucose and insulin, total cholesterol) measured at that 
visit were used for the adjustment in the logistic regression analyses of the current studies. The next 
follow-up took place average 3.5 years after the original examination including also the blood 
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sample for DNA analyses and the screening of cognitive performance for detecting dementia and 
memory disorders (demographic interview, clinical examination, six neuropsychological tests 
including MMSE). From the 1192 subjects still living and eligible (then 69 to 78 years old) 
ultimately 980 (82 % of the original sample) participated in this first dementia screening (Koivisto 
et al., 1992; Helkala et al., 1995; Kuusisto et al., 1997). The second similar cognitive follow-up 
evaluation was carried out in 1992 and the third in 1993-94 (Helkala et al., 1995) approximately 
seven years after the first clinical examination and three to four years after the first cognitive 
screening. A total of 632 (71 %, then 72-82 years old) of the 890 eligible subjects were completely 
evaluated at this last follow up evaluation by 1994 (Helkala et al., 1995). The clinical and cognitive 
condition of all of the study subjects was followed up from available medical records and the settled 
dementia diagnoses from the National Research and Development Centre for Welfare and Health 
statistics up to 2003. The survival of the whole study group was followed up to 1995, and that of the 
subjects with AD in 1997 and 2003. In addition, the medical records were evaluated from a total of 
319 study subjects, who did not participate in the first cognitive screening phase. The crucial 
interventions and formation of the study population during follow up are shown also in table 7. 
The subjects with suspected memory disturbances in the screening evaluations underwent more 
detailed differential diagnostic examinations including several neuropsychological tests, clinical 
neurological, laboratory, radiological and neurophysiological examinations (Koivisto et al., 1992; 
Helkala et al., 1995). Dementia was diagnosed according to DSM-III-R criteria (APA, 1987) and 
AD according to the NINCDS-ADRDA criteria (McKhann et al., 1984). Controls neither showed 
any deterioration in repeated cognitive tests nor developed any kind of cognitive disorder in later 
life. The subjects with types of cognitive disturbances other than AD, missing genetic information 
or insufficiently studied cognitive performance were excluded from the study. 
The cognitive evaluation of the study group as well as the diagnosis of dementia and follow up of 
the subjects with dementia were carried out by the Brain Research Unit (former Memory Research 
Clinic), Department of Neurology and Neuroscience, University of Kuopio and in the Department 
of Neurology, Kuopio University Hospital (Koivisto et al., 1992; Helkala et al., 1995). 
For the study I survival analyses, all of the subjects originally participated in the first clinical 
examination were analysed. Grouping to the AD patients and controls was made according to first 
cognitive evaluation. Forty eight subjects were diagnosed to have AD at that time. Further survival 
analyses and evaluation of daily ability were examined in that group (48 AD subjects). 
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In study II 65 AD subjects were identified by 1994 and for the study IV a total of 125 AD subjects 
by 2003. The probable AD diagnosis was made as described above and confirmed after follow-up 
of the clinical course of the disease. All the control subjects had participated in the last cognitive 
screening without any signs of cognitive deterioration. The subjects who did not participate in the 
last cognitive evaluation or did not undergo the more detailed diagnostic examinations in the case of 
suspected memory deficit, subjects with types of dementia other than AD, subjects with a suspicion 
of some disease interfering with the cognitive performance (e.g. depressed subjects) or the subjects 
with missing the crucial genetic information were excluded from the analyses of these studies. 
Furthermore, for study IV, we checked that control subjects had not been iued with any dementia 
diagnosis by 2003. 
Study III 
In study III, all the subjects were examined in Department of Neurology, Kuopio University 
Hospital and University of Kuopio. To confirm the homogeneity of the study group, the community 
based voluntary, unrelated control subjects were derived from the same restricted area of northern 
Savo as the AD patients. That area was settled in the late 16th and early 17th century (Soininen, 
1981; Pirinen, 1982). All the participants were interviewed for demographic information, medical 
history, current medication, living habits and subjective assessment about memory disturbances or 
depression during the past year also for this study. Family data of dementia was obtained from the 
medical records, interviewing the study subject or by interviewing the next of kin (in the case of 
individuals with dementia). In addition to the interview, all the controls underwent at least one to 
three cognitive screening tests (Wechsler, 1945; Benton, 1974; Folstein et al., 1975).The interview 
and cognitive screening tests were carried out by trained personnel (nurse, psychologist or doctor) 
during a single visit. Standardization of the interview and tests was accomplished with the help of 
an instruction manual. The blood sample for DNA genotyping was taken at the same visit.  
Controls exhibited no signs of dementia during the interview and neuropsychological testing at the 
time of the cognitive evaluation.  
All AD subjects underwent a comprehensive clinical evaluation (including clinical and neurological 
examination, neuropsychological testing, imaging study of the brain and laboratory tests) based on 
which the clinical diagnosis of possible or probable AD was made according to the NINCDS-
ADRDA criteria (McKhann et al., 1984; APA, 1987).  
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These 891 study subjects who participated in study III included 354 LOAD cases (84% of all AD 
cases) and 68 EOAD cases (16% of all AD cases with onset age 65 years or below). Sixty three of 
EOAD subjects were screened for known AD mutations in APP, PSEN-1 or PSEN-2 genes. 
Although no such mutations were found, it is still possible that some of these patients may carry 
rare variants in these genes. Approximately 40% of AD patients displayed a positive family history 
of AD (at least another first-degree relative with AD type dementia), but there was inconclusive 
evidence of autosomal dominant transmission. If no reliable family history was available, patients 
were termed as sporadic cases. 
4.2. Methods  
4.2.1. Clinical and laboratory examinations  
The clinical examination was similar to the comprehensive neurological examination regularly 
performed in clinical practice, including medical history, physical examination directed especially 
towards cardio- and cerebrovascular problems, detailed neurological examination and assessment of 
mental state, especially depression and cognitive functions.  
Blood pressure was measured in the supine position with a mercury sphygmomanometer after 5 
minutes rest. Two readings were taken with a 1.5 minutes break. The latter value was used in the 
statistical analyses.  
Blood samples were taken in the morning after 12 hours fasting. Venous blood samples for glucose 
and insulin determinations were taken into chilled tubes. Plasma glucose was determined by the 
glucose oxidase method (Glucose Auto & Stat HGA-1120 analyzer, Daiichi, Kyoto, Japan). Plasma 
insulin was determined from samples stored at -70ºC by a commercial double-antibody solid-phase 
radioimmunoassay (Phadeseph Insulin RIA 100, Pharmacia Diagnostics AB, Uppsala, Sweden) 
(Hales and Randle, 1963). Commercial enzymatic methods and control sera were used in the 
determination and standardizing the measurements  of total cholesterol (Monotest, Boehringer 
Mannheim, Mannheim, Germany; Seronorm and Seronorm Lipid, Nycomed, Oslo, Norway) (Siedel 
et al., 1983). 
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4.2.2. Neuropsychological tests  
Neuropsychological screening tests were carried out by psychologist during a single visit. 
Standardization of the tests was accomplished with the help of an instructional manual. 
Neuropsychological evaluation for studies I, II and IV included six neuropsychological tests 
(Reitain, 1958; Borkowski et al., 1967; Buschke and Fuld, 1974; Folstein et al., 1975; Russel, 1975; 
Butters et al., 1987) which were repeated at the follow-up visits.The MMSE total score adjusted for 
education (cut off scores were 23, 24 or 25) was used for clinical phase examinations. Also, those 
subjects scoring one or more standard deviations below the mean on at least three of the above 
specified subitems of four other screening tests were considered to be potentially demented.  
In Study III, most subjects underwent three cognitive screening tests (Wechsler, 1945; Benton, 
1974; Folstein et al., 1975) with cut off points in MMSE >25, in Benton visual Retention test >6 
and in Paired Associate learning subtest >13 without history of memory impairment in the 
interview. These tests are described in detail previously (Hanninen et al., 1997). Fifty one controls 
were screened only by MMSE with a higher cut off point (27 points or more, no signs of impaired 
delayed recall of words) and interview (no subjective memory complaints or signs of memory 
impairment during the interview) (Hiltunen et al., 2001). 
MMSE includes a selection of short items testing different aspects of cognitive function like 
orientation, repetition and recall of words, attention, language and constructional ability. The score 
used was the sum of the scores of all items (Folstein et al., 1975). 
In the Buschke Selective Reminding Test (BSRT) the subject has to recall as many as possible of 
the ten words that have just been read out by the examiner. The scores obtained are the total number 
of words and the words which were recalled in consecutive trials without being repeated (i.e. words 
in long term memory) (Buschke and Fuld, 1974).  
Visual Reproduction Test (VRT) includes three subtrials in which the person must reproduce 
increasingly complex geometric, nonrepresentative features from memory immediately after seeing 
them and after 30 minutes of unrelated testing. In order to assess any visuoperceptual dysfunction, 
the subject is asked to copy the figures after the recall. The scores are given for the number of 
components present in the original drawings. The maximum score in each of three subitems is 21 
(Russel, 1975). 
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Verbal Fluency tests (VFTs) includes two parts. First the subjects are given 60 seconds to produce 
as many words as possible beginning with each of the letters P, A and S (VFT-letters). For the VFT 
category, the subject is asked to generate the names of as many animal names as possible within 60 
seconds. The performance was scored by counting the total number of correct words produced for 
each letter or category. Study I analysed the results from VFT-L (Borkowski et al., 1967; Butters et 
al., 1987). 
Study I used Trail Making Test (TMT) part A where the subjects must draw a line to connect 
consecutively numbered circles. The scores are the time required to complete the trial. The time 
limit is 150 seconds (Reitain, 1958). 
In the Benton Visual Retention test, form C, administration A (BVRT), the subject copies from 
memory ten different figures after their presentation for ten seconds. The scores are awarded for 
each correctly reproduced figure (Benton, 1974). 
In Paired Associate Learning subtest (PAL) of the Wechsler memory Scale (WMS), the examiner 
reads ten pairs of words. The subject is afterwards required to recall the latter word of each pair 
when the first one is presented as a cue. This procedure is repeated three times. The total score was 
calculated according to the specific manual for this test (Wechsler, 1945). 
4.2.3. Determination of apolipoprotein E phenotype (studies I, II and IV) 
The ApoE phenotype was determined from venous serum samples with isoelectric focusing of 
heparin/Mg2+ -precipitated lipoproteins and immunoblotting techniques using commercial 
antibodies as described in detail (Ehnholm et al., 1986; Menzel and Utermann, 1986). 
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4.2.4. Gene analyses 
For studies II-IV, genomic DNA was extracted from peripheral blood leukocytes using the standard 
phenol/chloroform extraction method (Vandenplas et al., 1984). 
Table 8. Primers used in the PCR and SNaPshot  analyses. 
Study      Gene  Target Location  Used Primers  
Study II:  IL-6   
    Promoter   F: 5’-TGACTTCAGCTTTACTCTTTGT-3’ 
        r: 5’-CTGATTGGAAACCTTATTAAG-3’ 
 
Study III: CYP46  
     5’ to exon 6  F: 5’-ATTGCTCAAGGACAGGCAGT-3’ 
        R: 5’-GCTGTTCCCTTGCTCTTGTC-3’ 
      SNaPshot  5’-T40GGCCACAGTGACCAACAGAG-3 
    Intron 2    F: 5'-AAT GCA TGC TAC CAA AAG AG-3' 
        R: 5'-AAT CAT TTG ATT CCC AGG AC-3' 
      SnaPshot 5’-T31CAACAGGGCAGAGCCTTGCCCCC-3’ 
  SERPINA3   
    Intronic dbSNP:4934 F: 5'-CAG AGT TGA GAA TGG AGA-3' 
        R: 5'-TTC TCC TGG GTC AGA TTC-3' 
      SnaPshot 5’-T38AGAGAATGTTACCTCTCCTG-3’ 
  APOE     F: 5'-GCACGGCTGTCCAAGGAGCTGCAGGC-3' 
        R. 5'-GGCGCTCGCGGATGGCGCTGAG-3' 
 
Study IV: 
  PPARγ   Exon B  F: 5'-GACAAAATATCAGTGTGAATTACAGC-3' 
        R: 5'-CCCAATAGCCGTATCTGGAAGG-3' 
     Exon 6  F: 5'-CCGCCCAGGTTTGCTGAATGTG-3' 
        R: 5'-CAGTGGCTGAGGACTCTCTG-3' 
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IL-6 (study II) and PPARγ (study IV) 
The PPARγ exon B and exon 6 as well as the IL-6 promoter were analyzed by PCR with the primers 
shown in Table 8. The PPARγ variants and the IL-6 C-174G polymorphism were detected by single 
strand conformation polymorphism analysis. The screening of the studied polymorphisms in the 
PPARγ and IL-6 has been described previously (Laakso et al., 1994; Valve et al., 1999).  
CYP46, SERPINA3 and APOE (Study III)  
For CYP 46 and SERPINA3 gene analyses the studied SNPs were validated from the National 
Center for Biotechnology Information (NCBI) data library. Two intronic SNPs investigated in 
CYP46 gene were dbSNP:754203 T-to-C substitution in intron 2, and >14kb distant in an intronic 
dbSNP:2146238 G-to-T substitution 5’ to exon 6. In the SERPINA3 gene, an intronic dbSNP:4934 
A-to-G substitution was determined. Assays for the SNPs were genotyped in one multiplex 
polymerase chain reaction (PCR) to perform a single SNaPshot reaction. Forward and reverse 
amplification primers for each SNP were used as presented in Table 8. A product of each PCR-
amplification was used as a template in an ABI PRISM® SNaPshot™ Multiplex assay (Applied 
Biosystems) and specific primers (Table 8) were used in a SNaPshot reaction with the length of tail 
described: SNaPshot multiplex reactions were performed according to the manufacturer’s 
instructions and samples were analysed with ABI 3100 Genetic Analyzer and GeneMapper software 
(Applied Biosystems).  
For recognition of the APOE allele forms ε2, ε3 and ε4, PCR and HhaI (New England Biolabs) 
digestion of the PCR products were carried out with primers (Table 8) and conditions as previously 
published (Tsukamoto et al., 1993). The heterozygote APOE ε2/4 sample was used as control in 
each run. 
These gene tests were analyzed by two researchers independently. 
4.2.5. Statistical analyses  
The distributions of genotypes in studies II-IV, both in all and in stratified groups, were found to be 
in Hardy-Weinberg equilibrium (Genepop web version of 3.4). Statistical significance was 
established at P<0.05. 
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Study I 
The study population was divided first into two groups identified on the basis of the examinations 
in 1991: subjects with AD and control subjects and subsequently for the presence of ApoE ε4 
phenotype (ApoE ε4 carriers/ ApoE ε4 non-carriers) and gender.  
Data analysis was conducted with the SPSS /PC+ programs (6.1.). A multivariate Cox regression 
model (Cox, 1972) was used to investigate the association of risk factors with allcause mortality. 
Otherwise the χ2 -test or analysis of t-test was used in the assessment of differences between the 
studied groups.  
Study II-IV 
In the risk analyses, AD patients were compared to non-demented control subjects in the total study 
group and also stratified according to the presence of the ApoE ε4 phenotype (genotype in study III) 
or gender (study IV). In study IV, to estimate the difference in the age of AD onset, the AD patients 
were subdivided according to their genotypes. The relative risk of AD or difference in age of onset 
was estimated using two-tailed Pearson χ², Fischer exact or Mann Whitney tests, and adjusted 
logistic regression analysis (SPSS program, version 10.1) Adjustment was made with ApoE, age, 
gender, education and cardiovascular risk factors (systolic blood pressure, serum total cholesterol, 
fasting blood glucose) previously described to be in association with the risk of AD. Power 
determinations were performed using Query Advisor Release 3.0 software 
(http://www.statsol.ie/nquery/review3.htm). Estimation of haplotype frequencies for study III was 
performed with Arlequin version 2.0 (http://lgp.unige.ch/arlequin). Haplotype frequencies were 
compared for case and control subjects using the RxC-program employing the metropolis algorithm 
to obtain unbiased estimates for exact p-values with standard errors. 
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5. RESULTS 
For all these studies ApoE ε4 (or APOE ε4 for study III) allele and allele carrier frequencies were 
analyzed and compared between AD patients and control subjects. In every study presented in this 
thesis, as expected, the proportion of ApoE ε4 allele and this allele carriers were significantly higher 
among AD patients (p<0.001) compared to non-demented subjects (Table 6). The numbers of 
ApoE ε4 carriers and demographics of the study populations are presented in the "Subjects" part of 
this thesis in Table 6. 
5.1. Survival of AD patients in relation to ApoE phenotype (Study I) 
In all 4% of the total study group were diagnosed as having AD at the time of the first cognitive 
screening in 1990-91. Eight of them had already an AD diagnosis with early manifestations of the 
disease and the other 40 were diagnosed at the study visit. The distributions of the genders and 
ApoE ε 4 phenotype carriers are shown in tables 6 and 9. 
5.1.1. Survival of the whole study population 
During the seven years’ follow-up time of the whole study group, 12 (25.0%) of 48 AD patients and 
280 (22.4%) of 1251 controls died. This difference in allcause mortality as well as in stroke or 
cardiovascular mortality was not statistically significant between the groups (Table 9). AD patients 
were slighty older than controls (70 vs. 69 years)  but this did not influence mortality. With respect 
to the analysed risk factors, the ApoE phenotype (ApoE ε4 non-carriers vs. ApoE ε4 carriers) did 
not influence survival, nor did the presence of AD, whereas the risk of mortality was significantly 
higher among men than among women (131/ 30% of 471 men and 151/ 18% of 828 women died, 
p<0.001) (Table 10). There was no significant difference in age between men and women at 
baseline (mean age of both groups was 69 years).   
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Table 9. Characteristics and mortality of study subjects after seven years of follow-up (Study I).  
 
 All Subjects with 
Alzheimer’s 
disease 
Controls 
Number of subjects 1299 48 1251 
Men/Women 471/828 16/32 455/796 
ApoE4+ 420 (30.9) 27 (56.3) 393 (31.5)* 
All Cause mortality 292 (22.5) 12 (25.0) 280 (22.4) 
Stroke mortality  35 (2.7) 3 (6.3) 32 (2.6) 
CHD mortality 119 (9.2) 3 (6.3) 116 (9.3) 
The χ2 -test *p<0.001; Values are numbers (percentages); ApoE+= one or two ApoE ε4 allele; 
CHD= coronary heart disease 
 
Table 10. Univariate Cox regression analysis on risk factors (Sex, ApoE ε4, AD) of mortality 
during seven years’ follow-up in aged subjects (65-74 years in baseline). 
 
 HR 95% CI p value 
Sex 
(Men/ Women) 
0.56 0.44 - 0.70 <0.001 
ApoE4 
(0/1) 
0.95 0.74 - 1.22 0.692 
Alzheimer’s disease 
(no/yes) 
1.18 0.61 - 1.93 0.784 
HR= Hazard Ratio; 95% CI= 95 % ConfidenceI; ApoE 0/1= Subjects not carrying ApoE ε4 allele 
(marked as 0) compared to subjects carrying at least one ApoE ε4 allele (marked as 1). 
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5.1.2. Survival of the AD patients in relation to gender and ApoE phenotype 
The subjects with AD (N=48) were followed up for a further two years. Twenty six (54%) of them 
were still alive and 22 (46%) had died by 1997. Of those still alive, 11 had severe, six moderate, six 
mild and two still exhibited early dementia, data from one of those 26 still alive was missing. 
Fifteen subjects with AD were living at home (eight of them alone and six without any major need 
of help, data on one was missing ) and 11 were in a nursing home or hospital. At the cognitive 
screening visit in 1990-91, the survivors (AD patients living in 1997) and the non-survivors (died 
AD patients by 1997) had the same age (mean age, range in years: 70±2 (65-74) in survivors vs. 
71±3 (65-74) in non-survivors) and duration of dementia from thr onset of symptoms (mean 
duration, range in years: 2.9±4.6 (0-15) in survivors vs. 3.6±3.7 (0-12) in non-survivors), but in 
baseline cognitive testing, those patients deceased by 1997 had had lower scores in MMSE (mean 
MMSE points, range: 22±3 (17-28)  in survivors vs. 19±5 (9-26) in non-survivors, p=0.01) and the 
verbal memory in BSRT (mean points, range: 21±5 (8-30) in survivors vs. 17±4 (7-24) in non-
survivors, p<0.01), but not in Visual Reproduction Test (VRT) assessing visual memory, TMT or 
Verbal Fluency Test. 
Of all AD patients, 52% of subjects with the ApoE ε4 phenotype and 38% of subjects without ApoE 
ε4 had died by 1997 (Table 11). At cognitive screening the ApoE subgroups did not differ in age or 
performance in cognitive tests. Although mortality was higher in Apo ε4 carrier AD subjects than in 
ApoE ε4 non-carrier patients, the difference was not significant (p = 0.31). However, mortality in 
the ApoE ε4 non-carriers males (80% had died) was significantly higher than that of the women 
(20% had died)(Table 11). 
Table 11. Mortality of the patients with Alzheimer’s disease according to the ApoE phenotype and 
gender in 1997. 
 ApoE4- 
 
      All             Men*      Women 
ApoE4+ 
 
   All            Men         Women 
Survivors 13 1 12 13 5 8 
Non-survivors 8 5 3 14 5 9 
Total number 
of subjects 
21 6 15 27 10 17 
ApoE4- = subjects with apolipoprotein ε 2/2, 2/3 or 3/3 phenotype; ApoE4+ = subjects with 
apolipoprotein ε 2/4, 3/4 or 4/4 phenotype. χ2 -test *p<0.01 between genders in ApoE4- 
group;Values are numbers of subjects. 
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5.2. Interleukin-6 polymorphism and risk of AD (study II) 
The frequency of finding the IL-6 -174 G allele was significantly higher (p= 0.03) among ApoE ε4 
non-carrier AD subjects, but not  in the total study group or the ApoE ε4 carriers (Table 12). The 
CG and GG genotypes in ApoE ε4 non-carrier AD patients were also more common than in ApoE 
ε4 non-carrier controls but not statisticaly significantly (Table 12). When we combined the 174- 
CG or GG genotypes, we found a borderline risk for AD of the G allele carriers compared to the 
subjects with CC genotype in a univariate test (OR 3.4, 95%CI 1.0-11.4; p= 0.04) but after 
adjustment, this finding did not reach significance (OR 3.4, 95%CI 1.0-12.0; p= 0.06). In the total 
study group or the ApoE ε4 carriers, no significant differences were observed for allelic or genotype 
distributions of IL-6 -174 G/C promoter polymorphism (Table 12). 
No significant additive influence on the risk of AD was found between ApoE ε4 and IL-6 -174 G 
allele carriers (Table 13). 
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Table 12. IL-6 -174 G/C promoter polymorphism genotype and allele distributions in AD cases and controls. 
 
   Genotypes Alleles 
Group  n CC CG GG OR(95%CI); P ¹ C G OR(95%CI); P ² 
All AD 65 0.23 0.49 0.28  0.48 0.52  
 CO 542 0.27 0.48 0.25 1.3 (0.8-1.9); 0.27 0.51 0.49 1.2 (0.8-1.7); 0.44 
ApoE4- AD 29 0.10 0.52 0.38  0.36 0.64  
 CO 388 0.28 0.46 0.26 1.7 (0.9-2.9); 0.08  0.51 0.49 1.8 (1.1-3.2); 0.03  
ApoE4+ AD 36 0.33 0.47 0.20  0.57 0.43  
 CO 151 0.26 0.53 0.21 0.9 (0.5-1.7); 0.68 0.52 0.48 0.8 (0.5-1.4); 0.48 
n= Number of Alzheimer's disease patients (AD) and controls (CO);  
ApoE4- = Apolipoprotein E ε 2/2, 2/3 or 3/3 phenotype;ApoE4+ = Apolipoprotein E ε 2/4, 3/4 or 4/4 phenotype; The ApoE status was missing in 
three control subjects; Only uncorrected P-value used. 
¹ Adjusted binary logistic regression analysis was performed in three groups (all, ApoE4- and apoE4+). ApoE, age, sex, education and 
cardiovascular risk factors (blood pressure, total cholesterol and fasting insulin values) previously associated with AD as covariates were used in 
the regression model. 
² Pearson χ² test used to analyse allelic data. 
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Table 13. Adjusted odds ratios for AD with ApoE ε4 non-carriers and IL-6 CC genotypes as a 
reference. Total study group (n=604).  
ApoE4 IL-6 G AD Controls OR(95% CI)* P
- - 3 109        1.0  
- + 26 279 3.4(1.0-12.0)    0.06
+ - 12 39 14.8(2.9-74.8) < 0.01
+ + 24 112   8.5(2.3-31.2) < 0.01
  65 539   
 
AD=Alzheimer's disease; ApoE4 (ApoE 2/2, 2/3, 3/3 phenotypes= -; ApoE 2/4, 3/4, 4/4 
phenotypes= +); IL-6 -174 G/C (174CC genotype= -; 174CG/GG  genotypes= +); 
ORs with 95% Confidence Interval (CI) for AD were calculated using binary logistic regression 
models and they were adjusted for age ,gender, education, systolic blood pressure, fasting total 
cholesterol and insulin; Statistical significance (P) was established at <0.05. 
 
5.3. Cholesterol 24 -hydroxylase (CYP46) polymorphism and risk of AD (Study III) 
The distribution of APOE ε2, ε3 and ε4 alleles in the AD and controls was 0.02/0.51/0.47 and 
0.04/0.80/0.16, respectively. The APOE ε4 allele was significantly associated with AD (OR 4.8) as 
described in table 6 and age at onset was approximately three years earlier for APOE ε4 carriers vs. 
ε4 non-carriers (71 vs. 74 years, p<0.001). In chi-square and logistic regression tests, the subjects 
were also split on the basis of APOE genotype into the APOE ε4 carriers and non-carriers (Table 14 
and 15).  
No significant differences were observed for allelic or genotype frequencies of dbSNP: 2146238 
between AD patients and controls. However, a strong pairwise LD (D’=0.99; p<0.001) between 
dbSNP:754203 and 2146238 was found in all samples (1782 alleles) or in AD case and control 
groups, separately. 
The results show that a significant association between dbSNP:754203 CC genotype and AD was 
observed in all subjects and in subjects  carrying APOE ε4  (Table 14). The age and sex adjusted 
odds ratio for the risk of AD in the carriers of the dbSNP:754203 CC genotype was 2.13 (95% CI 
1.25 to 3.62; p=0.005) and 3.58 (95% CI 1.21 to 10.56; p=0.021) compared with the CT/TT 
genotypes for all and APOE ε4  carrier group, respectively. Table 15 describes the combined effects 
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between the dbSNP:754203 CC and APOE ε4 genotypes. We found an increased risk of AD (OR 
3.34) in the subjects with both the dbSNP:754203 CC genotype and APOE ε4  allele, taking as 
reference subjects those who had neither of these genotypes. Thus, we determined whether our 
results support an independent or synergistic model of these two genes. Our finding of the predicted 
OR 21.4 in those having both risk genes separately in the binary regression model (data not shown) 
compared to the OR in the subjects with the combined risk effect (3.34) suggested strongly to an 
independent model of action for these two genes. 
For the meta-analysis of the dbSNP:754203, fifteen case-control studies, including subjects from 
this study, were pooled to achieve a total of 3307 cases and 3328 controls (table 16). Fixed effects 
meta-analysis was performed since the likelihood ratio test did not provide any significant evidence 
of between-study heterogeneity (χ2 = 20.49, df =14; p=0.12). In the pooled analysis of different 
ethnic populations, a pooled effect of CC-genotype frequencies in AD cases was very similar to 
those found in controls (OR 1.16; 95% CI 0.97 to 1.38). We also estimated a pooled effect of C-
allele frequencies in all populations with random effects meta-analysis, finding OR 0.95; 95% CI 
0.83 to 1.10. 
In haplotype analysis, haplotypes for dbSNP:754203 and 2146238  with the following frequencies 
CG, 31% in AD vs. 26% in controls; TG, 53% vs. 56%; TT, 16% vs. 18% were included into 
statistical tests. Haplotype analysis with 844 alleles in all AD cases and 938 alleles in all controls 
showed that CG haplotype was more common in AD cases than in controls (p<0.03).  
The frequency of the SERPINA3 dbSNP:4934 for A-allele was 54.8% in AD cases and 56% in 
controls. No association between SERPINA3 and AD was found.  In addition, non-significant LD 
(D’=0.001; p=0.97) between CYP46 and SERPINA3 markers was observed. 
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Table 14 CYP46 genotype and allele distributions for dbSNP:754203 
Genotypes, n (%) Alleles, n (%) Group n 
CC CT TT 
Pa 
C T 
Pb 
All AD 422 43 (10) 172 (41) 207 (49) 258 (31) 586 (69) 
 CO 469 24 (5) 196 (42) 249 (53) 
0.015 (0.030) * 
244 (26) 694 (74) 
0.040 (0.080) * 
APOE4- AD 111 12 (11) 43   (39) 56   (50) 67   (30) 155 (70) 
 CO 340 20 (6) 145 (43) 175 (51) 
0.203 
185 (27) 495 (73) 
0.391 
APOE4+ AD 311 31 (10) 129 (41) 151 (49) 191 (31) 431 (69) 
 CO 129 4   (3) 51   (40) 74   (57) 
0.032 (0.062) * 
59   (23) 199 (77) 
0.019 (0.038) * 
          
 
aFisher’s exact test and bunbiased estimate of exact p value. *To compensate for multiple testing, we used the Bonferroni method and corrected 
for two tests (APOE4 status). APOE4- = Apolipoprotein E ε22/23/33 genotypes and APOE+ = Apolipoprotein E ε 24/34/44 genotypes. n= 
number of subjects. AD= Alzheimer’s disease; CO=controls. 
 
Table 15 Age and sex adjusted odds ratios for AD with APOE ε4  non-carrier and CYP46 dbSNP:754203 CT/TT genotypes as a reference   
 
APOE4 CYP46 CC AD, n (%) CO, n (%) OR (95% CI) a Pa 
- - 99    (24) 320  (68) 1 (reference)  
- + 12    (3) 20    (4) 2.03 (0.92-4.47) 0.81 
+ - 280  (66) 125  (27) 2.89 (2.46-3.41) <0.001 
+ + 31    (7) 4      (1) 3.34 (2.26-5.03) <0.001 
  422 469   
 
aOdds ratios (ORs) were calculated using binary logistic regression model. APOE4 (24/34/44 genotypes= +; 22/23/33 genotypes= -) and CYP46 
CC (CC genotype= +; CT/TT genotypes= -).  
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Table16. Meta-analysis of the dbSNP:754203 CC-genotype carriers.  
Study (Population) AD (n/N) Control (n/N) OR (fixed) 95% CI Weight % 
15Desai (USA)  45/434 41/401 1.02 (0.65-1.59) 16.33 
15Desai (African American; USA)  1/54 2/61 0.56 (0.05-6.32) 0.79 
16Ingelsson (USA) # 19/178 5/105 2.39 (0.86-6.60) 2.40 
17Wang (China)  2/99 3/113 0.76 (0.12-4.62) 1.17 
11Combarros (Spain)  27/321 10/315 2.80 (1.33-5.89) 3.95 
8Papassotiropoulos (Greece, Italy) 5/107 6/76 0.57 (0.17-1.95) 2.86 
8Papassotiropoulos (Switzerland) 7/94 19/172 0.65 (0.26-1.60) 5.31 
18Borroni (Italy)  10/143 10/134 0.93 (0.38-2.32) 4.10 
19Kabbara (France)  57/601 57/631 1.06 (0.72-1.55) 21.51 
13Kölsch (Germany)  10/115 16/144 0.76 (0.33-1.75) 5.54 
20Chalmers (UK) # 4/86 3/58 0.89 (0.19-4.15) 1.46 
14Johansson (Sweden) 54/440 45/398 1.10 (0.72-1.67) 17.72 
14Johansson (Sweden) # 5/93 11/102 0.47 (0.16-1.41) 4.24 
14Johansson (Scotland) ¤ 9/120 11/149 1.02 (0.41-2.54) 3.88 
Present study (Finland)  43/422 24/469 2.10 (1.25-3.53) 8.73 
     
Total (95% CI) 
 
3307 3328 1.16 (0.97-1.38) 100.0 
 
OR and 95% CI of the genotype frequencies are shown. #Autopsy-confirmed sample; 54 AD cases confirmed (Ingelsson). ¤Early-onset AD 
sample. n/N=  Number of CC-genotype carriers/ Number of subjects.  Weight % = Weighting proportion of each individual study (used when 
combining ORs). In the separate pooled analysis of USA and European populations, a pooled effect of CC-genotype frequencies was similar to 
those found in controls (OR 1.17; 95% CI 0.78 to 1.73 and OR 1.16; 95% CI 0.95 to 1.41, for USA and European, respectively).  
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5.4. The peroxisome proliferator-activated receptor γ polymorphism and AD (study IV) 
The distributios of the ApoE alleles ε2/ ε3/ ε4 were significantly different (p<0.001) in subjects 
with AD (0.02/0.66/0.32) compared to controls (0.07/0.80/0.13). 
The allele or genotype frequencies of PPARγ exon 6 C478T ( C/T allele and CC/CT/TT genotype 
frequencies in AD patients vs. controls: 0.80/0.20 vs. 0.81/0.19 and 0.62/0.35/0.03 vs. 
0.64/0.33/0.03)  and exon B encoding for Pro12Ala (Pro/Ala allele and ProPro/ProAla/Ala/Ala 
genotype frequencies in AD patients vs. controls: 0.86/0.14  vs. 0.85/0.15  and 0.74/0.24/0.02 vs. 
0.72/0.26/0.09) did not differ significantly between AD cases and controls in the total study group 
or in subgroups stratified by ApoE ε4 phenotype or gender. The additive influence of the combined 
PPARγ exon 6 C478T and Pro12Ala genotype for the risk of AD was also studied with 478CC and 
Pro12Pro as reference. No significant additive influence on the risk of AD was found in the total 
study group or in the stratified groups.  
The influence of the PPARγ C478T or Pro12Ala genotypes on age of onset was studied in the total 
AD group. Interestingly, AD subjects carrying both PPARγ 478T and 12Ala allele, that is the less 
common of each allele, manifested clinical AD significantly earlier than the subjects without these 
alleles (75 years vs. 78 years, p= 0.026, Table 17). Furthermore, we studied whether the 
significance of 12Ala-478T carrier genotype on age of onset was influenced by confounding 
factors. The AD group was dichotomized according to the mean age of onset (77 years) and groups 
were compared using Pearson χ² tests and adjusted logistic regression models. This significance 
seemed to be independent from the adjusted variables (Table 18). The influence of the 12Ala 
variant or 478T allele carrier genotypes separately on the age of onset did not quite reach 
significance (p= 0.057 and p=0.068 respectively). Furthermore, the ApoE phenotype di not 
influence the age of onset in this aged AD population (ApoE ε4 carriers vs. non-carriers, age of 
onset in both groups was 77 years). 
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Table 17. The additive influence of combined  PPARγ Pro12Ala and exon 6 C478T genotypes on 
age of onset in total AD group (n= 125) with Pro/Pro-C/C as reference. 
Pro12Ala C478T N Age of onset P 
Pro/Pro C/C 71 77.6±5.3 1 
Pro/Pro C/T or T/T 22 77.3±4.6 0.597 
Pro/Ala or Ala/Ala  C/C  7 77.4±3.9 0.957 
Pro/Ala or Ala/Ala  C/T or T/T 25 75.4±4.7   0.026* 
 
Pro/Pro, Pro/Ala and Ala/Ala = PPARγ2 Pro12Ala variants; C/C, C/T and T/T= PPARγ exon 6 
C478T genotypes; N= number of subjects carrying each genotype combination; Age of onset 
given as years ± SD; Mann Whitney test used in statistics. 
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Table 18. The effect of 12Ala and 478T carrier genotype on age of onset (onset ≤77 year, N=25 or onset >77 years, N=75) in AD patients with 
Pro/Pro-C/C carriers as reference . Pearson χ² test and adjusted binary logistic regression tests. 
 Model 1  Model 2  Model 3  
 P  OR(95%CI) P  OR(95%CI) P OR(95%CI) 
Ala+ /T+ 0.018 3.4 (1.2-9.4) 0.022 3.5 (1.2-10.3) 0.014 4.0 (1.3-12.1) 
ApoE4+ - - 0.753 0.9 (0.4-2.1) 0.764 0.9 (0.3-2.2) 
Sex - - 0.547 0.7 (0.3-1.9) 0.396 0.7 (0.2-1.7) 
Age at baseline - - 0.337 0.9 (0.8-1.1) 0.373 0.9 (0.8-1.1) 
systolic BP - -   0.317 1.0 (1.0-1.0) 
TC - -   0.870 1.0 (0.6-1.4) 
Gluc     0.150 1.2 (0.9-1.6) 
Model 1: Univariate test, Pearson χ² test used;  
Model 2: Adjusted binary logistic regression. Adjustment made with ApoE ε4, gender and age at baseline. 
Model 3: Adjusted binary logistic regression. Adjustment made with the variables used in Model 2 and also with the cardiovascular risk factors 
previously associated with AD (systolic blood pressure, fasting total cholesterol and fasting glucose); 
Ala+/T+ = combined PPARγ 12Ala and exon6 478T carries; ApoE4+ = apolipoprotein E ε4 carriers; systolic BP= systolic blood pressure; TC = 
fasting total cholesterol; Gluc = fasting glucose; OR (95% CI) = Odds Ratio with 95% confidence interval. 
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6. DISCUSSION 
6.1. Methodological aspects 
6.1.1. Study populations and design 
The strength of the present study is in the homogeneity of these Caucasian patients and control 
subjects. The Finns are generally considered as being genetically isolated. In our study, both study 
patients and controls were derived from a geographically restricted area in northern Savo or Kuopio 
city. Homogeneity of the study population is essential for the genetic association studies but due to 
this genetic isolation, the reported results are mainly validated in our population can not be 
generalized to other populations.  
Men and women were represented equally in both AD and control groups. The patients were on 
average slightly older and less educated than the controls but this was taken into account when the 
results were adjusted in multivariate analyses to verify the findings.  
Considering the possibility to find true differences between the compared groups, there was an 
adequate number of  subjects in the whole study populations (in studies I-IV) but the number of 
subjects in AD group became finally quite limited in studies I, II and IV (48 subjects in study I, 65 
subjects in study II and 125 subjects in study IV). When the subjects  (Studies I, II and IV) were 
invited for the follow-up study  we were only able to estimate how many of them would convert to 
the dementia during the next years. In 1990-91 the numbers of identified AD cases (3.7.%) out of 
all study of the subjects resembles the prevalence of AD in this age group (Ott et al., 1995). During 
several years follow-up time, naturally, some of the study subjects died and some others did not  
respond to the next study invitation (Helkala et al., 1995). Some of the patients were not willing to 
provide a DNA sample or were not otherwise eligible for these genetic studies.  
In studies I, II and IV all the subjects were LOAD cases with comparable clinical phenotype and 
duration of the disease at the beginning of the follow-up. In study III, some of the study subjects 
(both controls and AD subjects) were under 65 years. Most of them were screened for the known 
EOFAD mutations without any findings, and none of the AD cases showed an autosomal dominant 
inheritance in their family. Thus, it is more likely that they share a similar genetic background as 
the LOAD subjects.  
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In 1997, the AD patients’ need of maintenance in everyday life (for study I) was evaluated by 
interviewing the caregivers over the phone. This method provides more reliable picture of the 
patients’ current situation than can be obtained by interviewing patients themselves. It is possible 
that selection of a face-to-face approach would have been even more informative. The diagnosis of 
AD was made using widely accepted criteria for dementia and AD. For studies II and IV, the AD 
subjects were accepted as cases if also the clinical course of the disease had followed the “classical” 
progression of this disease 
Also controls, not only demented subjects, were interviewed to evaluate their ability of daily living 
and cognitively screened by at least one neuropsychological test, usually with several tests. For 
studies II and IV they were followed up for years and for study IV their cognitive survival was 
estimated by checking the dementia diagnoses in 2003. For that study, the controls had survived 
without any cognitive symptoms for the whole follow up period.  The subjects named as controls in 
study I  included also cases with other cognitive problems. Several of study I and II controls 
developed also clinical AD during the later years of their lives. Also, study IV, which is a classical 
case control study, we cannot exclude the possibility that some controls would have suffered AD 
after the study and this would obviously affect the results. However, this same problem is shared 
with most of the studies conducted around the world. 
All the personnel who carried out the examinations and finally made the diagnoses were trained and 
qualified to identify subjects with cognitive disturbances. On the other hand,  due to the several 
years follow-up, some of the personnel changed. This might have influenced some of the 
estimations during the examinations. 
6.1.2. Cognitive screening tests 
Widely used, and replicable neuropsychological screening tests were selected to examine different 
aspects of learning and different kinds of memory functions (e.g. MMSE- delayed word recall, 
orientation, VFT- long term semantic memory, VRT, BSRT- to ability to to learn and retain verbal 
or pictorial information) but also to estimate the subject’s attentional state and ability to solve 
problems ( e.g. MMSE, TMT). Education, age and gender were taken account in the cognitive 
performance which was noted during the interview considering the ability to take care of everyday 
life. All the subjects were capable of performing the tests at the beginning of the follow-up study or 
at the time of the cognitive screening in the study III. 
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The more tests, repetitively used after follow-up, to test different kinds of memory functions, the 
better we may identify the subjects with memory problems. Therefore, a rather wide selection of the 
neuropsychological tests were performed and in the most cases, repeated once or twice. 
Furthermore, an interview may reveal the deterioration of the cognitive functions compared to the 
level the subject had in the earlier phase of the life. A minority of the study IV controls performed 
only one neuropsychological test (MMSE). In view of the weakness of one test to recognize 
cognitive decline, we performed the interview and elevated the MMSE cut off point in these 
controls (MMSE ≥27 without history of the memory impairment by the interview). We postulate 
that demented subjects were excluded also by this method from controls, but we cannot exclude the 
possibility that some control subjects may have some milder cognitive disturbances. 
6.1.3. Diagnosis of AD 
The diagnostic procedure consisted of the interview of the study patients and also the caregivers and 
the wide range of differential diagnostic examinations used in clinical practice. These detailed 
examinations were carried out by experienced personnel. The diagnosis of AD was accepted if 
made according to the golbally used DSM-IIIR criteria for dementia (APA, 1987) and NINCDS-
ADRDA criteria for AD (McKhann et al., 1984). Therefore, we are convinced that the diagnosis of 
clinical AD was made as well as possible. According to several studies, the accuracy of the clinical 
AD diagnosis is around 85-90%, the definite diagnosis of AD requires neuropathological 
confirmation of typical AD changes in brain. To obtain as accurate an AD diagnosis as possible for 
studies II and IV, the progression of the disease was one criterion to be fulfilled (WHO, 1993) with 
other characteristic symptoms and findings typical to this dementing disease. 
6.1.4. Selection of susceptibility risk genes  
All the studied candidate susceptibility genes for AD risk were selected for the analyses as 
biological candidate genes based on previous studies indicating that the proteins the genes encode 
have been implicated in AD pathophysiology and/or there is evidence of the functional changes in 
the specific genes caused by single polymorphisms. This is the other generally accepted method to 
select possible new genes for association studies as in the current study.  
We concentrated on the genes which share at least theoretically the possibility to affect 
inflammatory mechanisms (PPARγ, IL-6 and SERPINA3) (McGeer and McGeer, 1998; Landreth 
and Heneka, 2001; Papassotiropoulos et al., 2001; Cheng et al., 2002) and/or lipid metabolism and 
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atherosclerosis (PPARγ, IL-6, CYP46 and APOE) (Lund et al., 1999; Papassotiropoulos et al., 2001; 
Plutzky, 2003; Raffai and Weisgraber, 2003). By the time the study was completed, the 
pathophysiological mechanisms (inflammation and lipid metabolism) in which these genes are 
involved have become an area of great interest in AD research and consequently the genes possibly 
regulating these reactions are the focus of much research activity. On the other hand, the impact of 
selected genes, like many other AD candidate susceptibility genes, seems to be quite limited and 
appear to be evident only in small subgroups of AD. The most interesting of the currently studied 
genes may be PPARγ which may regulate the expression of other genes and influence, in theory, 
directly the neuroinflammatory responses seen in brain (Landreth and Heneka, 2001; Sastre et al., 
2006). 
6.1.5. Molecular genetic analyses 
The methods we used to study the genes (SNPs and haplotype) and ApoE phenotype are widely 
used and validated. ApoE phenotype was determined from venous samples at the time (at the 
beginning of the 1990’s) when genetic analyses were not available yet. There is no absolute 
concordance between genotype and phenotype method. Analyses of the Framingham Offspring 
Study (Lahoz et al., 1996) have revealed that a discrepancy may occur in 3% of the cases. However, 
both methods resulted in similar ApoE allele frequencies and for example, no differences were 
observed regarding the average allelic effect on total cholesterol (Lahoz et al., 1996). 
6.1.6. Statistical analyses 
We used the diagnosis of AD (study I survival analysis), alleles or genotypes and haplotypes of 
studied polymorphisms as primary categorical variables in these analyses. This is a common 
approach in epidemiological and genetic studies, providing a possibility to study odds ratios (risk of 
the disease caused by the studied factor) through application of univariate tests and logistic 
regression. All the used statistical tests throughout the study are in general use and easy to repeat. 
On the other hand, the possibility of false positive findings increases when multiple tests are used. 
In these cases, Bonferroni correction was used to correct the level of significance as e.g. in study 
III. 
In genetic studies focussing on complex diseases such as AD, the signal obtained from association 
analyses is believed to be more prominent than that obtained from linkage studies. Moreover, 
identification of genes and single polymorphisms as well as statistical methods used in these kinds 
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of studies are easily carried out and replicated in the other study populations. While the number of 
studied genes and also the significant findings from these kinds of studies are high, the replicated 
studies achieving similar results are few and false positive findings may also occur. Also, the effect 
of the possible single gene on AD risk is low, perhaps being influenced by other genes and several 
other non-genetic factors. We tried to take this into account by adjusting in the logistic regression 
model for cardiovascular risk factors previously associated with AD risk (Kuusisto et al., 1997; 
Breteler, 2000; Kivipelto et al., 2001b), gender, age and education as well as with ApoE phenotype. 
The adjusted factors were selected due to their association with AD in previous studies. All the 
study subjects were Caucasians, thus the adjustment with race was not appropriate. Age is the most 
important risk factor for LOAD (Ott et al., 1995) and the effect of some genes as AD risk factors 
may also be age dependent as in the case of APOE (Ott et al., 1995; Slooter et al., 1998. Protective 
effect of early life education for AD is well described {Fritsch, 2002 #145) Protective effect of 
early life education for AD is well described (Fritsch et al., 2002) and higher socioeconomic status 
including higher education affect general health and consequently survival (Roberge et al., 1995). 
Lifetime risk of dementia for women is twice as high as for men, which reflects not only the longer 
life span of women but also the higher dementia risk at very old age (Ott et al., 1998). Adjusted 
cardiovascular risk factors (high blood pressure, glucose and insulin metabolism and total 
cholesterol levels) used in the studies II and IV have been associated with increased LOAD risk in 
clinical studies (Kuusisto et al., 1997; Breteler, 2000; Kivipelto et al., 2001b). Based on the 
evidence that these cardiovascular factors may affect AD risk prior to the clinical onset of the 
disease (Kivipelto et al., 2001b) we used the values measured at the clinical baseline i.e., before the 
disease had become clearly manifested in these study subjects. Furthermore, PPARγ and IL-6 
polymorphisms or the proteins encoded by these genes are involved in the regulation of 
inflammation, lipid metabolism and atherosclerosis (Lund et al., 1999; Papassotiropoulos et al., 
2001; Plutzky, 2003; Raffai and Weisgraber, 2003). These adjusted factors are a major research 
focus for AD risk in their own right and also, they may interact with the possible candidate genes 
for AD risk. Therefore, it was important to study the effect of these factors in relation to AD risk 
caused by the studied polymorphisms.  
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6.2. Apolipoprotein E, gender and late-onset AD- effect on survival  
6.2.1. ApoE, gender and LOAD in relation to survival in the aged population 
The frequencies of ApoE ε4 in both controls and AD subjects in studies I, II and IV were 
comparable to other previously published population based data from the same geographical area 
(Lehtovirta et al., 1995; Kivipelto et al., 2002a).  
Middle-aged carriers of the ApoE ε4 phenotype are known to have an unfavourable lipid-profile 
and increased risk of cardiovascular diseases, and consequently increased risk of death (van 
Bockxmeer and Mamotte, 1992; Wilson et al., 1994; Wilson et al., 1996) but, in elderly subjects the 
results have been contradictory (Kuusisto et al., 1995; Olichney et al., 1997; Heijmans et al., 2002; 
Lane et al., 2003). This is most likely due to increased mortality risk (4.8 fold) in ApoE ε4 carriers 
compared to E3/3 carriers when they are younger, suggesting that the carriers of the ApoE ε4 have 
died before entry into these studies which are conducted in aged populations. This is supported by 
the reduced ε4 allele frequency in the aged compared with young cohorts (Talmud et al., 2004). 
Cerebrovascular deaths have not been reported to be increased in the aged carriers of ApoE ε4 
(Kuusisto et al., 1995; Olichney et al., 1997). In the case of intracerebral hemorrhage (ICH) Woo et 
al (Woo et al., 2002) reported that in a comparison of ApoE with ICH location, the ApoE ε2 and ε4 
allele carriers had increased risk of lobar ICH.  
In the present study, we did not find any significant difference between subjects with AD and non-
demented subjects in their risk of succumbing to cardiovascular disease or stroke. Our results 
confirm the reports that the importance of the ApoE ε4 phenotype as a risk factor for cardiovascular 
and also stroke deaths decreases with age (Kuusisto et al., 1995; Olichney et al., 1997; Talmud et 
al., 2004). Although the ApoE ε4 phenotype did not seem to be an important risk factor for 
cardiovascular or cerebrovascular deaths in this aged population, mortality from these diseases does 
increase with ageing. For example, the risk of stroke among the elderly has been reported to double 
with each successive decade of life (Wolf et al., 1992). 
Furthermore, we studied the influence of gender and AD on survival duration. In our study, in line 
with one other study (Corder et al., 1995), the survival of women was significantly longer than thet 
of men. The longer survival of women was independent of ApoE phenotype. Meanwhile, we were 
unable to show, in contrast to two other studies, that the presence of AD had any influence on 
survival in our aged study population (Olichney et al., 1997; Larson et al., 2004). Larson with his 
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colleagues from U.S. reported in 2004 (Larson et al., 2004) that in the subjects who received a 
diagnosis of AD (in both EOAD and LOAD subjects) the survival duration was shorter than 
predicted on the basis of the national population data. In contrast to our study, they studied also the 
survival of the EOAD patients and it seemed that especially within that group was the survival 
duration shortened. This may be one possible reason for the difference between the results from our 
study and those of Larson. 
6.2.2. ApoE and gender in relation with survival in LOAD 
While the effect of the ApoE ε4 allele in AD risk is clear, the effect in the course of the disease and 
survival of the AD patients is stil a matter of depate. For example, Tilvis et al reported (Tilvis et al., 
1998) that the Apo E ε4 carrier phenotype correlated with increased mortality in AD patients 
studied in a population based sample while Slooter et al (Slooter et al., 1999b) did not find any 
relation between APOE ε4 allele and survival in AD. In the present study among all AD patients, 
we coud find no significant influence of ApoE ε4 carrier genotype on AD survival. Subsequently 
on, results consistent with our study and also with the Tilvis study have been published (Dal Forno 
et al., 2002; Fillenbaum et al., 2002). However after stratification of the AD population according to 
gender, ε4 negative men with AD had higher mortality compared to ε4 negative woman with AD. 
One has to bear in mind that there were only six ε4 negative men with AD and a false positive 
finding due to small sample size cannot be excluded. On the other hand, previous studies have 
suggested that the risk of death in men with AD is increased (Corder et al., 1995) and progression of 
AD is faster in Apo E ε4 non-carriers (Frisoni et al., 1995; Stern et al., 1997). 
6.2.3. Neuropsychological tests and survival 
We report that the progression of AD may be predicted by the results achieved in MMSE and BSR 
at the time of diagnosis. Larson et al, in line with our results, have reported that reduced survival 
correlated with severity of cognitive impairment (poorer results in MMSE and Blessed) at the time 
of diagnosis(Larson et al., 2004). This suggests that non-survivors were suffering from a more 
advanced form of the disease at entry. In the present study, the duration of AD did not explain the 
difference in survival nor did the ApoE phenotype. On the other hand, it has been observed that 
some subtypes of AD, for example Lewy body variant of AD, are characterised by faster cognitive 
decline and increased mortality (Drachman et al., 1990). It is also likely that many environmental 
and genetic factors contribute to the progression of AD. It would be necessary to conduct a more 
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detailed evaluation of clinical features, environmental factors and neuropathological and genetic 
data to confirm this suspicion. 
6.3. Susceptibility genes and risk of AD  
6.3.1. An allelic association of IL-6 polymorphism in AD risk 
Previously two SNPs (IL-6 -174 G/C and VNTR polymorphisms) have been investigated in relation 
to AD risk in different populations with inconsistent results (Bagli et al., 2000; Bhojak et al., 2000; 
Papassotiropoulos et al., 2001; Shibata et al., 2002; Faltraco et al., 2003; Licastro et al., 2003; 
Arosio et al., 2004; Capurso et al., 2004; Depboylu et al., 2004; Nishimura et al., 2004). Capurso et 
al (Capurso et al., 2004) interpreted their study results and from estimations of other published data 
that geographical background could well have affected the results. This encouraged us to evaluate 
the role of the IL-6 -174 G/C promoter polymorphism in relation to LOAD risk in our population 
based sample.  
Our results are in line with the Shibata (Shibata et al., 2002) and the Pola (Pola et al., 2002) studies 
that ApoE ε4 non-carrier AD patients had significantly higher IL-6- 174G allele frequency with OR 
1.8 compared to controls. Furthermore, in the same group, CG and GG genotypes were more 
common in AD patients compared to controls but, possibly due to the limited number of AD cases, 
this was not statistically significant. On the other hand, in allsubjects or in the ApoE ε4 carrier 
group, we did not find any allelic or genotype associations in agreement with previous reports from 
German (Bagli et al., 2000) and other Italian populations (Bagli et al., 2000; Capurso et al., 2004). 
Interestingly, the G allele frequency was lower in our population in both AD patients (0.52) and in 
controls (0.49) compared to the respective values for to German (0.60/0.58) or Italian (0.75/0.77) 
study populations (Capurso et al., 2004). This supports the previous observation made by Capurso 
about the increasing geographical distribution of the IL-6-174 G allele from northern to southern 
Europe as being a possible, at least a partial, explanation for the controversial results (Capurso et 
al., 2004).  
The IL-6-174 G/C polymorphism, G allele as risk factor, is interesting in view of the findings by 
Fishman et al (Fishman et al., 1998) in their study evaluating in healthy controls and subjects with 
juvenile chronic arthritis. They reported (Fishman et al., 1998) that IL-6-174 C construct was 
associated with lower expression of IL-6 gene and lower IL-6 plasma levels and, on the contrary, 
that the IL-6-174 G  allele as a risk factor increased the expression of IL-6 gene and IL-6 plasma 
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levels. They proposed that there is genetically determined difference in the degree of the IL-6 
response to stressful stimuli between individuals and that the CC genotype of this polymorphism is 
a potentially protective genotype. Based on these findings, the IL-6 genotype may be relevant also 
in other conditions in which IL-6 is implicated (Fishman et al., 1998). 
There are studies which have evaluated the impact of the IL-6 in the pathophysiological reactions 
seen in AD. Elevated production of IL-6 has been linked to the early stages of amyloid deposition 
and plaque formation, leading to the neurodegenerative process seen in AD (Gruol and Nelson, 
1997). Consistently, IL-6 and other cytokines can be stimulated in glial cells surrounding Aβ 
plaques in an animal model of AD (Mehlhorn et al., 2000) and in cultured cells (Toro et al., 2001). 
Recently, Luterman et al (Luterman et al., 2000) found higher IL-6 mRNA expression in both 
entorhinal cortex and superior gyrus of AD patients with an advanced stage of the disease compared 
to normal controls. This difference was not noted between the AD patients at an earlier stage of the 
disease and controls (Luterman et al., 2000). They suggested that the inflammatory cytokine 
response to the pathological effects of AD does not occur until the later stages of the disease 
(Luterman et al., 2000). The factors which are responsible for the overexpression of IL-6 are not 
clear but it appears that age is an important factor for IL-6 (Wei et al., 1992; Ye and Johnson, 
2001). 
Since ApoE is an established risk factor for AD (Corder et al., 1993; Saunders et al., 1993), the 
interaction with APOE genotype has been studied in relation to IL-6 polymorphisms and AD but 
there is no evidence for any possible synergistic effect (Arosio et al., 2004; Depboylu et al., 2004) 
even though Bhojak et al (Bhojak et al., 2000) did find in ApoE ε4 carriers a marginal association 
between GC/GG genotypes and increased AD risk compared to CC carriers. Here we could not 
detect any synergistic effect in the AD risk between ApoE ε4 allele and the IL-6-174 CG/GG 
genotype. 
6.3.2. The CYP 46 and SERPINA3 polymorphisms and risk of AD 
The present candidate gene based association study with the CYP46 gene in a large series of AD 
and controls found evidence for an increased AD risk in the CYP46 dbSNP:754203 CC genotype 
carriers in all subjects and APOE  ε4 carriers. Our data of an association between dbSNP:754203 
CC genotype and AD is in line with a study in the Spanish population (Combarros et al., 2004). 
However, a significant risk in AD patients carrying CC genotype was only evident in these Spanish 
subjects with APOE ε4 genotype. This discrepancy between results of these two different ethnic 
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populations may be due to differences in the APOE frequencies. The frequency of the APOE ε4 
allele was 16% in our controls and only 6%, in the study of Bullido et al (Bullido et al., 1998) in 
their Spanish population. It seems also that dbSNP:754203 CC genotype may not possess an 
additive risk effect within APOE ε4 carriers in our population and thus our data supports an 
independent risk factor mode of action for APOE and CYP46 genes.  
To test whether there exists LD in the CYP46 gene, we screened another marker dbSNP:2146238. 
Our finding of considerable LD (D’) between SNP pairs (dbSNP:754203 and 2146238) showed a 
robust intermarker association, which may be evidence of a haplotype block structure as also 
described by SNPbrowser™ software (Applied Biosystems). Although the dbSNP:2146238 
polymorphism failed to show a single allele association between cases and controls, we observed 
that the  CG containing haplotype exhibited a modest odds ratio of 1.25 for the risk of AD.  
There are several published contradictory studies describing either no association or even an 
opposite effect of dbSNP:754203 T/C and AD. Although the results for a significant association of 
dbSNP:754203 T/C and AD may be population specific and related to AD via some unknown 
mechanism, the meta-analysis argues against the hypothesis that the dbSNP:754203 T/C plays a 
crucial role between the CYP46 gene and AD. Since the relevant variation dbSNP:754203 T/C is 
intronic, it is not clear how it can influence the function of the enzyme coded by this gene (Kolsch 
et al., 2002; Johansson et al., 2004). The dbSNP:754203 T/C LD may reflect a pathogenic variation 
in the CYP46 gene itself but it may also, be present in a nearby gene. A genetic association with AD 
has earlier been found in the dbSNP:4934 of the SERPINA3 gene. However, our data from a single 
marker seems to exclude SERPINA3 gene as a candidate gene for AD. The frequency of SERPINA3 
A-allele (previously AD risk related allelic form) was equivalent in AD patients and in controls. In 
addition, no significant LD between CYP46 and SERPINA3 polymorphic markers was observed, 
which most likely rules out any genetic association between the genes. It remains to be tested 
whether the dbSNP:754203 T/C may be in LD with functionally relevant variability elsewhere in 
the CYP46 gene. 
6.3.3. PPARγ polymorphisms in risk of AD and age of disease onset 
While we could not find an association between studied PPARγ polymorphisms on AD risk in line 
with Sauder and colleagues (Sauder et al., 2005), our data does suggest that the carriers of both 
12Ala and 478T allele have a lower age of onset (OR 3.4) compared to Pro12Pro/478 CC carriers. 
This modifying effect on age of LOAD onset seems to be independent of ApoE and other adjusted 
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variables. Interestingly, in the present study there were no significant differences in age of LOAD 
onset between ApoE ε4 carriers and non-carriers as described previously (Slooter et al., 1998).  
These PPARγ loci have been previously described to be associated with increased body fat-mass 
(Deeb et al., 1998; Valve et al., 1999; Cock et al., 2004), insulin sensitivity and unfavourable lipid 
profile (Deeb et al., 1998; Cock et al., 2004) which are factors also associated with the risk of AD 
(Breteler, 2000). Therefore the 12Ala/478T carrier genotype rather than being be a direct risk 
factor, may represent a disease course modifying factor for developing AD. This theory finds 
support from the findings that the PPARγ variant carrying the polymorphic region coding Pro12Ala 
is expressed extensively in adipose tissue (Meirhaeghe and Amouyel, 2004). Furthermore, the 
chronic inflammatory reaction related to AD may be regulated by PPARγ agonists (Combs et al., 
2000). On the other hand, our data suggested that the earlier age of AD onset related to the PPARγ 
Pro12Ala and C478T polymorphism was independent from the studied cardiovascular risk factors. 
The recent findings by Sartre et al. support the concept for a role for PPARγ as a modulator of the 
β-amyloid generation by inflammation (Sastre et al., 2006). A direct functional impact on the 
activity of PPARγ is also possible in the modulation of the AD development as are also changes in 
the transactivation of the PPARγ gene in the case of the Pro12Ala polymorphism (Deeb et al., 
1998). The possible functional mechanisms of the silent C478T polymorphism remain unknown. 
To evaluate whether the allele number used in the analysis was sufficient to find a true association, 
a power analysis was also undertaken. According to the simulation analysis, on the basis of the 
Ala12Pro or C478T minor allele proportions described previously in this area population (Valve et 
al., 1999), approximately 600 alleles or 300 subjects, respectively would have been needed in each 
group to have a statistically significant p-value of 0.05  at 70% power and a moderate odds ratio 
(OR) of 1.5 
6.3.4. Importance of the findings in AD risk and implications for the future 
In the case of IL-6 we showed that IL-6 prom 174 G- allele is over-represented in Finnish LOAD 
patients, at least in those LOAD patients not having any ApoE E4 alleles. Also, CYP46 is a possible 
risk gene for Finnish AD patients. However, in the case of CYP46, the meta-analysis argues against 
the hypothesis that the dbSNP:754203 T-to-C plays a crucial role generally between the CYP46 
gene and AD. Our data seems to exclude SERPINA3 gene as a candidate gene for AD but indicate 
that polymorphisms within the PPARγ gene in exon 6 C478T and in the region coding Pro12Ala 
can modify age of onset in LOAD independently of ApoE phenotype. While no direct genetic 
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influence on AD risk was found, this data in conjunction with a previous report (Sauder et al., 2005) 
suggests that the studied PPARγ polymorphisms do not play a role in AD risk in these European 
populations.  
The genetic associations between PPARγ, CYP46 and IL-6 and AD would highlight the importance 
in the disease development of the immune functions and lipid metabolism of brain. The recently 
published data related to studied polymorphisms and the alteration of their function as well as the 
clarification of the functions of the encoded proteins in brain support the findings of the genetic 
association studies. Thus also indicates that the studied genes are pathophysiologically relevant 
susceptibility candidate genes for AD. 
However, the results of these studies should be interpreted with some degree of caution.  This 
caution applies in particular to the results from the ApoE stratified tests, owing to the smaller 
sample size in the study groups, and when the results are principally based on one intronic marker. 
These approaches increase the possibility of false positive findings.  
Furthermore, there are several issues from a genetic point of view which are not yet clearly 
resolved. There are several polymorphic sites in the studied genes which need to be identified if 
possible and examined. In that way, one can determine which site has the strongest signal for AD, 
how they influence gene expression and what are the kinds of functions or the pathophysiological 
effects of the encoded proteins. The gene to gene as well as the gene to environmental interactions 
in relation to the studied genes are unknown. It would be interesting to determine, whether these 
polymorphic genes can influence the therapeutical response to drugs. Should it be the case that 
these genes are involved in AD, it is likely that the effect of one gene in the complex disease risk 
(i.e. AD risk) is quite small. However, in view of the previous reported associations with conditions 
related also with AD, IL 6, CYP46 as well as SERPINA3 and PPARγ remain interesting candidate 
susceptibility genes for dementia. Confirmation of the association between these genes and AD as 
well as investigating their functional role in the pathogenesis of AD will be challenging task for 
researchers in the future.To sum up, this data supports the theory that several susceptibility genes 
contribute to the risk of AD development.  
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CONCLUSIONS 
1. The presence of ApoE ε4 phenotype or AD did not influence the risk of mortality in the elderly 
population while the risk of death was significantly increased in men compared to that of women. 
Once AD had manifested itself, the ApoE ε4 carrier phenotype did not influence the survival.  
2. Our findings point to an influence of IL-6 on the LOAD risk in ApoE ε4 non-carriers in the 
Finnish population and consequently, support the hypothesis for an involvement of IL-6 in AD. 
3. The CYP46 is a possible risk gene for Finnish AD patients or it reflects the influence of a nearby 
gene which increases the AD risk. On the other hand, the meta-analysis with dbSNP:754203 T/C 
argues against this hypothesis. Furthermore, the evaluation of a nearby gene SERPINA3 
polymorphism did not detect any significant association between this gene and risk of AD.  
4. No direct genetic influence on LOAD risk was for the polymorphisms in PPARγ  and the AD 
risk. Instead, PPARγ seem to modify the  age of onset in LOAD independently of ApoE phenotype.  
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